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ABSTRACT 
Sievers, Sherri A. D.N.P. College of Nursing and Health, Wright State University, 2012. 
Development of A Best Evidence Statement (BESt) For Confirmation of Nasogastric 
(NGT) or Orogastric Tube (OGT) Placement. 
 
 
 
The purpose of this scholarly project was to develop a Best Evidence Statement (BESt) 
for the confirmation of nasogastric or orogastric tube placement in hospitalized children.  
The nose-ear-xiphoid (NEX) method of measurement and auscultatory method of tube 
verification is commonly used but is unreliable and has resulted in misplaced tubes as 
well as poor patient outcomes.  Radiography is considered the gold standard however the 
risks outweigh the benefits due to excessive radiation exposure, increases in healthcare 
costs and delay in delivery of care.  Methods which utilize bedside testing and proper 
tube measurement have been shown to be effective in nasogastric tube (NGT) or 
orogastric tube (OGT) verification.  Gastric pH has been shown to be an accurate method 
of bedside testing with a pH of < 5 confirming placement in the stomach.  In addition, 
age-related height-based (ARHB) methods have been shown to be an accurate method of 
predicting tube length.  The Iowa Model of Evidence-Based Practice to Promote Quality 
Care was used to guide development of evidenced-based care recommendations that were 
published as a BESt statement at Cincinnati Children’s Hospital Medical Center and 
through The Agency for Healthcare Research and Quality’s (AHRQ) National Guideline 
Clearinghouse (NGC).  The BESt recommendations include tube length prediction using 
ARHB methods and pH testing of gastric aspirate. 
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I. Problem 
Description of the Problem 
Hospitalized pediatric patients often require nasogastric tube (NGT) or orogastric 
tube (OGT) insertion for the therapeutic purpose of administering enteral feedings and 
medications, or for gastric decompression.  Feeding tubes are required for children who 
display clinical symptoms of feeding and swallowing disorders.  Common symptoms 
include a weak or poor suck-swallow pattern, breathing disruptions, coughing or choking, 
poor oral, tongue, lip and jaw control, delayed swallow, recurrent pneumonia and upper 
respiratory infections, aspiration, failure to thrive, malnutrition, weight loss, prolonged 
feeding time, and unexplained refusal to eat (Skitberg & Bantz, 1999).  Children who are 
comatose, semi-comatose, or have swallowing problems are at high risk for placement 
errors outside the intended location (Ellett & Beckstrand, 1999).   However, every child 
who is receiving a tube is at risk for tube placement errors.  
Determination of proper tube placement is an important part of safe nursing 
practice.  Properly placed tubes are those which are placed orally or nasally and terminate 
in the stomach. However, NGT’s can be placed incorrectly into the brain, airway, pleural 
cavity, esophagus or peritoneum (Ellett & Beckstrand, 1999).  Error rates for placement 
of enteral tubes in any location, other than the intended location, can be up to 43.5% in 
pediatric settings (Ellett & Beckstrand, 1999).  A small percentage of those misplaced 
tubes, reported as 1%-4% in adult intensive care settings but unknown in pediatrics, are 
incorrectly placed within the respiratory tract with potentially serious consequences 
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(Ellett, Croffie, Cohen, & Perkins, 2005; Metheny, Eikhov, Rountree, & Lengettie 1999b; 
Metheny et al, 1994a). 
Prevention of medical errors should be taken seriously.  The Institute of Medicine 
(IOM) (1999) released the report To err is human: building a safer health system which 
estimated at least 44,000 and possibly as many as 98,000 people die in hospitals each 
year as a result of medical errors.  In a follow-up report, Crossing the quality chasm: a 
new health system for the 21
st
 century, IOM (2001) outlined six specific aims for 
improvement of the American health care system.  It is proposed health care should be 
“safe, effective, patient centered, timely, efficient and equitable” (p. 51).  This report 
launched a major federal initiative to reduce medical errors and improve patient safety.   
The IOM (2001) defines an adverse event as one that results in “unintended harm to the 
patient by an act of commission or omission” (p 32).  The Joint Commission (n.d.), an 
independent, not-for-profit organization who evaluates the quality and safety of care for 
health care organizations, has also addressed the issue of medical errors.  In 1996 the 
Joint Commission implemented the sentinel event policy to address the issue of safety 
events.  A sentinel event is defined as “an unexpected death or serious physical injury, 
including loss of limb or function, or psychological injury, or the risk thereof” (Joint 
Commission, 2011, p.1).  “Risk thereof” refers to incidents that may have not caused 
harm but a recurrence of the error would carry a significant chance of a serious adverse 
outcome.   The sentinel event policy is designed to help institutions identify events which 
could cause harm and take action to prevent future recurrence.  When a sentinel event 
occurs, an institution is expected to analyze the cause of the event, make improvements to  
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reduce risk, and monitor the effectiveness of the improvements (Joint Commission, 
2011).   
Significance of the Problem  
Safety is a top priority for Cincinnati Children’s Hospital Medical Center 
(Cincinnati Children’s) who declares, “Safety is central to delivering the best-in-class 
outcome” (Cincinnati Children’s Hospital Medical Center, 2012a, p.1).  Cincinnati 
Children’s is a full service, not-for- profit pediatric academic medical center serving 
children locally, nationally and internationally.  The vision of Cincinnati Children’s is to 
be “the leader in improving child health” (Cincinnati Children’s Hospital Medical Center, 
2012b, p.1).  The mission statement expands on this idea and aims to “improve child 
health and transform delivery of care through fully integrated, globally recognized 
research, education and innovation while striving to achieve the best medical and quality-
of-life outcomes, patient and family experience, and value” (Cincinnati Children’s 
Hospital Medical Center, 2012b, p.1).  Cincinnati Children’s has 577 registered inpatient 
beds accounting for 30,951 admissions for fiscal year 2011 (Cincinnati Children’s 
Hospital Medical Center, 2012c) while providing care to patients from newborn to 21 
years of age.  
Insertion of NG tubes is common practice at Cincinnati Children’s in addition to 
other pediatric hospitals.  The supply purchasing department estimates that over 10,000 
tubes are placed annually at Cincinnati Children’s (G. Graham, personal communication, 
September, 2012).  NGT/OGT’s are typically placed at the bedside by registered nurses 
(R.N.) or physicians.  Cincinnati Children’s uses the nose-ear-xiphoid (NEX) method of 
measurement combined with the auscultory method for NGT or OGT placement 
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verification.  Radiographic verification is not routinely done but is recommended for 
patients at high risk for aspiration.   
  Prior to the start of this project, Cincinnati Children’s reported a safety event 
resulting from an incorrectly placed NGT using the NEX and auscultory methods.  
Therefore, recognition that misplaced tubes could result in an adverse or sentinel event 
was documented.  Improper placement of NG tubes into the lungs can cause 
pneumothorax or pneumonia, which could lead to sentinel events (Ellett et al., 2005; 
Metheny et al., 1999b; Metheny et al, 1994a).  In response to the resulting safety event at 
Cincinnati Children’s, a group was formed to examine the literature pertaining to 
placement of NGT/OGT’s and a guideline was developed.  However, the guideline was 
not implemented related to issues with clarity of the statement, presentation of the data, 
and feasibility of the recommendations.  Instead the NGT/OGT insertion policy was 
modified to require that all patients who had a NGT/ OGT placed have an x-ray to 
confirm placement. However, after being in place for only two weeks, the policy was 
placed on hold when several problems were encountered after implementation.  Initially, 
the radiology department could not handle the increase demand for x-rays.  Secondly, 
patient care was delayed related to long wait times requiring transport to radiology and 
processing of films.  Lastly, patients and families complained about the inconvenience 
and expense of having to obtain an x-ray.  The policy was revised again requiring x-rays 
for patients who were obtunded, sedated, unconscious, critically ill or those that 
presented with a reduced gag reflux.  In addition, an x-ray could be obtained on any 
patient for which there were concerns about the tube being properly placed.  However the 
desire to develop a clear and feasible guideline for NGT/ OGT, which is reflective of the 
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literature, remained despite revisions and thus became the basis for this project.  
Therefore, the project targeted hospitalized pediatric patients who required NGT /OGT 
placement for feeding, medications, or decompression at Cincinnati Children’s. A large 
number of hospitalized children at Cincinnati Children’s require feeding tubes and the 
desire was to find a safe and evidence-based method for correct NGT/OGT placement 
and assessment.  
An evidence-based practice (EPB) approach was used to identify an accurate 
method of NGT/OGT placement in hospitalized pediatric patients who require NGT/ 
OGT placement for feedings, medications, or gastric decompression.  Radiography is the 
gold standard for documenting tube placement because of the extremely small margin of 
error, which is attributed to human error from misread films (Ellett & Beckstrand, 1999; 
Metheny & Meert, 2004).  However, routine radiologic verification in pediatric and 
adolescent patients increases the risk of excessive radiation exposure, increases patient 
and healthcare costs, and slows the delivery of clinical care (Ellett & Beckstrand, 1999; 
Neumann, Meyer, Dutton & Smith, 1995).  In addition, having to leave the hospital unit 
to obtain an x-ray can be inconvenient to the patient, family, and staff and portable x-rays 
are not always feasible.  Thus, it was necessary to find a method of NGT/ OGT 
placement that exemplifies safe clinical practice and also considers the needs and 
preferences of the patient and family, and staff. 
Methods of NGT or OGT verification which utilize nursing assessment skills and 
bedside testing are an alternative to radiography.  These methods include proper tube 
measurement, auscultation, gastric aspirate pH, enzyme tests, visual inspection of 
aspirate, and carbon dioxide (CO2) testing.   However, not all of these methods are highly 
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accurate nor are they always feasible to perform at the bedside (Metheny & Stewart, 
2002). 
Clinical practice guidelines are often used to guide nursing practice.  However 
guidelines related to the placement of NGT/OGT’s in pediatrics are limited.  Minimal 
guidelines were found in the literature.  The U.S. Department of Health and Human 
Services Agency for Health Research and Quality’s (AHRQ) holds the National 
Guideline Clearinghouse (NGC).  AHRQ’s mission is to improve the quality, safety, 
efficiency, and effectiveness of health care for all Americans (U.S. Department of Health 
and Human Services Agency for Health Research and Quality, 2012a).  The NGC’s 
mission is to provide physicians and other health professionals, health care providers, 
health plans, integrated delivery systems, purchasers, and others an accessible mechanism 
for obtaining objective, detailed information on clinical practice guidelines and to further 
their dissemination, implementation, and use (U.S. Department of Health and Human 
Services Agency for Health Research and Quality, 2012b).  The NGC is a public resource 
for evidence-based clinical practice guidelines and offers clinicians the most recent 
information about the continuum of care and best practices for all health care recipients 
(U.S. Department of Health and Human Services Agency for Health Research and 
Quality (2012c).  However, there were no clinical practice guidelines found related to the 
placement of NGT/OGT’s in pediatrics within the NGC.  
Best Evidence Statements (BESt’s) are similar to clinical practice guidelines and 
provide a format for the presentation of clinical recommendations, discussions, and 
methods in a user friendly way and are intended for publication (McGee & Clark, 2010).  
BESt’s are useful for the point-of-care clinician seeking concise evidence to guide 
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clinical decision-making (McGee & Clark, 2010).  The scope of a BESt is smaller than a 
clinical practice guideline.  According to Cincinnati Children’s Hospital Medical Center 
(2012d) a BESt contains a concise summary of the EBP review and presents clinical 
recommendations.  A BESt is based on high quality evidence related to a limited topic or 
single clinical question and depends more on synthesized evidence.  Synthesized 
evidence can include published guidelines and other systematic reviews when available, 
rather than primary research.  The BESt template is presented in Appendix A.    
This paper will discuss an EBP project development and publication of a BESt for 
confirmation of NGT or OGT tube placement for children.  After a description of the 
specific problem, target population, and impact of the problem, the Iowa Model of 
Evidence-Based Practice To Promote Quality Care (The Iowa Model) will be used as a 
guiding framework for BESt development.  
PICO Questions 
 One method of problem identification is utilization of the PICO question format.  
The acronym PICO represents the following: (P) patient, population or problem, (I) 
intervention or independent variable, I comparison, and (O) dependent variable or 
outcome (Stone, 2002). Using the PICO format, the purpose of this EBP project is to 
examine the following two questions: 1) Among pediatric patients who require 
NGT/OGT placement does auscultation, pH, enzyme, visual inspection of aspirate, and 
CO2 testing compared to radiological verification provide an accurate confirmation of 
tube placement?  2) Among pediatric patients who require NGT/OGT placements are 
tube length predictions using age-related height-based (ARHB) methods compared to 
nose-ear-xiphoid (NEX) morphological measurements more accurate in predicting tube 
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length?  The PICO questions will aid in determining the criteria for selecting studies to 
review and will serve as a guide for the remainder of the EPB process (Stone, 2002).  The 
PICO questions are broken down in Table 1. 
Table1 
PICO Questions for NGT/OGT Placement 
Format Specific clinical question 
component 
Rationale for selection of the specific component 
P Among hospitalized pediatric 
patients who require NGT or 
OGT placement 
Hospitalized pediatric patients frequently require NGT 
or OGT’s for enteral feedings, medication 
administration or gastric decompression. 
I does auscultation, pH, 
enzyme, visual inspection of 
aspirate, and CO2 testing 
Methods that are done at the bedside have been shown 
to be effective in accurate tube placement and have 
been associated with decreased costs, increased 
convenience. 
C compared to radiological 
verification 
Radiologic verification is the Gold Standard 
O provide an accurate 
confirmation of tube 
placement? 
Inaccurately placed  tubes can result in poor patient 
outcomes  including pneumothorax or pneumonia 
P Among hospitalized pediatric 
patients who require NGT or 
OGT placement  
 
Hospitalized pediatric patients frequently require NGT 
or OGT’s for enteral feedings, medication 
administration or gastric decompression. 
I are tube length predictions 
using age-related height –
based (ARHB) methods  
 
ARHB methods have been shown to be accurate 
predictors of tube length. 
C compared to nose-ear-xiphoid 
(NEX) morphological 
measurements 
NEX method is associated with a higher percentage of 
tube placement errors. 
O more accurate in predicting 
tube length? 
Tubes which are accurately measured result in higher 
incidence of properly placed tubes. 
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II. Evidence 
Evidence-Based Practice Framework  
The term EBP was introduced over ten years ago and evolved out of the concept 
of evidence-based medicine (EBM).  The terms EBM and EBP are often interchanged.  
Gray (2001) offered one of the earliest descriptions of EBM claiming it is “doing the 
right things right” (p 37).  Sackett, Richardson, Rosenberg and Haynes (1997) produced 
the first book on EBM, and defined it as “the conscientious, explicit and judicious use of 
current, best evidence in making decisions about the health care of patients”(p.18).  “Best 
research evidence” was defined by Sackett, Straus, Richardson, Rosenberg and Haynes 
(2000) as “taking previously accepted diagnostic tests and treatment and replacing them 
with new ones that are more powerful, more accurate , more efficacious and safer” (p.1) .  
Sackett et al. (2000) expanded the definition to include clinical expertise and patient 
values.  Patient values should take into consideration the “unique preferences, concerns 
and expectations of the patient” (p.1).  Clinical expertise is an important attribute of EBP.  
The success of the EBP guidelines that are being implemented, rely on the clinical skill 
and past experience of the nurse (Sackett et al., 2000).  LoBiondo-Wood and Haber 
(2006) contend that EBP should also include case reports and expert opinion.  
The Iowa model.  Many models have been developed to guide the development 
of EBP.  The Iowa Model originated in 1994, was revised in 2001 and has been used by 
providers as a guide to use research findings to improve patient care.  The Iowa Model
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 (Figure 1) guides the development of EBP by taking clinicians through several steps 
including: (a) identification of the practice questions or “triggers”, (b) priority of the 
topic, (c) forming a team, (d) assembling relevant research and related literature, (e) 
critique and synthesis of research, (f) decision on whether or not to implement research 
into practice, (g) pilot testing, (h) adaptation into practice, and (i) outcome assessment 
(Titler et al., 2001).   
In the first step, “triggers” are classified as either problem focused, or knowledge 
focused.  Examples of problem-focused triggers may include risk management data, 
process improvement data, financial data, benchmarking data, or identification of a 
clinical problem.  Knowledge focused triggers may relate to new research or other 
literature, national agency or organizational standards, philosophies of care, or questions 
from standards committees (Titler et al., 2001).  
Triggers must be a priority of the organization.  With a commitment to pursue a 
change in practice, a team is formed (Titler et al., 2001).  Team members should be 
multidisciplinary and represent all of the stakeholders involved in the project.  Teams 
may already exist or be newly developed. 
Next, the team will assemble, critique, and synthesize relevant research.  Titler 
and colleagues (2001) recommend one individual serve as the leader for the project, but 
to divide the work among the group.  Once studies are critiqued a decision to retain each 
study is made based on the overall merit of the study, the type of subjects and similarity 
to the project, and the clinical relevance of the study.  Summary tables can aid in 
summarizing information about the literature review. 
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Figure 1 
The Iowa Model 
 
 
Used/Reprinted with permission from the University of Iowa Hospitals and Clinics and 
Marita G. Titler, PhD, RN, FAAN. Copyright 1998. For permission to use or reproduce 
the model, please contact the University of Iowa Hospitals and Clinics at (319) 384-9090 
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A critical point in the process of the Iowa Model is determining if there is 
significant research to support a recommendation for a change in practice.  Determination 
is made by analyzing several factors: (a) consistency of the findings, (b) type and quality 
of the studies, (c) relevance of the findings, (d) number of studies similar to the sample, 
(e) the feasibility of the findings, and (f) the risk benefit ratio (Titler et al., 2001).  After 
sufficient evidence is found to support a practice change future steps would include pilot 
testing, adoption into practice, and outcomes evaluation.   
Needs Assessment/Triggers 
      In order to identify the triggers for this clinical problem and determine if there is 
organizational support, it is necessary to perform a needs assessment specific to the 
Cincinnati Children’s culture.  The population of interest was children newborn to 
nineteen years of age admitted to an inpatient unit (excluding the emergency department 
and neonatal or pediatric intensive care unit), at Cincinnati Children’s for any reason, 
which require a NGT/OGT for medication, feeding or decompression of the stomach.  
The key drivers or the triggers for this project were the history of a safety event and the 
potential for poor outcomes resulting from misplaced NGT/OGT’s.  In addition, 
Cincinnati Children’s commitment to safety and quality would also be considered a key 
driver.   
When a safety event occurs institutions are required to analyze the cause of the 
event and make improvements to reduce risk.  When Cincinnati Children’s encounters a 
problem related to nursing practice a referral is sent by risk management to the Nursing 
Practice Council.  In this case, a referral was sent related to the issue of misplaced 
NGT/OGT’s and after review; the Nursing Practice Council recommended a group be 
 
13 
formed to examine the evidence relating to NGT/OGT insertion.  A group was formed 
and in 2008 a BESt was published.  The BESt was then presented to the Nurse Practice 
Council for incorporation into a policy for NGT/OGT placement. In September 2008 as 
part of the Nursing Practice Council project I was given the task of incorporating the 
BESt into the new policy for NGT/OGT placement.  
At that time, nursing practice for confirmation of NGT/OGT placement consisted 
of measurement using NEX and auscultation.  The BESt described additional methods of 
placement verification, which included testing the pH of gastric aspirate.  Prior to this 
proposed change in practice it was necessary to assess readiness for change and support 
for the policy revision.  
Analysis for Readiness to Change/Priority of the Topic  
Analysis for readiness to change can be examined from both an institutional and 
specific setting perspective.  From an institutional perspective, the history of a safety 
event as well as the strong culture of safety lends support for a change in practice.  
Support from stakeholders is also important when instituting a new program.  
Stakeholders include those involved in program operations, those affected by the 
program, and the primary users of the program (Centers for Disease Control and 
Prevention (CDC), 1999, p. 5).  Key stakeholders for this project included members of 
the Cincinnati Children’s senior nursing administrative team, the directors of the inpatient 
units, physicians, nursing staff, education coordinators, laboratory staff, and nurse 
practitioner/Doctor of Nursing Practice (DNP) student (Appendix B).  In December 2008, 
the DNP student met with a small team of administrators, nursing leaders, and physicians 
to explore their commitment to the project and readiness for change.  The team expressed 
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support for change but raised concerns about the ability to perform bedside testing of pH 
of gastric contents.   
Bedside testing is federally regulated under the Clinical Laboratory Improvement 
Amendment (CLIA), which was passed in 1988 (Food and Drug Administration (FDA), 
2010).  These amendments established quality standards for all laboratory testing to 
ensure the accuracy, reliability, and timeliness of patient test results regardless of where 
the test was performed (FDA, 2010).  However, tests may be waived from regulatory 
oversight if they meet certain requirements established by the statute.  In the regulations, 
waived tests are defined as “simple laboratory examinations and procedures that are 
cleared by the FDA for home use; employ methodologies that are so simple and accurate 
as to render the likelihood of erroneous results negligible; or pose no reasonable risk of 
harm to the patient if the test is performed incorrectly” (FDA, 2010, p).  Bedside pH 
testing is included as one of the waived tests by the FDA.  The issue with CLIA waived 
tests is the tedious record keeping and documentation that is required as part of the 
regulation.  Failure to comply with the documentation guidelines could result in fines and 
sanctions.  Therefore, implementation of a practice guideline that utilizes a CLIA waived 
test was carefully considered. 
In February 2009, the DNP student met with a member of laboratory 
administration to further investigate the issue of bedside testing of pH.   The laboratory 
administrator confirmed that with proper training, monitoring and record keeping bedside 
testing of pH was possible because other bedside tests were done in the institution (L. 
Anderson, personal communication, February, 2009).  In May 2009 the DNP student met 
with the director of the nursing education coordinators to discuss the implications of a 
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policy change.  The education director supported the policy change but reported 
education for nurses would be necessary and could take up to six months to complete (A. 
Longo, personal communication, May, 2009),   
Through these meetings with the stakeholders it was evident that, although the 
project was a priority for the institution, there were potential barriers to implementation. 
However, consensus was that a change in practice would be considered if patient safety 
was the perceived benefit.  
The next step was to begin the policy revision.  However, when the DNP student 
closely examined the BESt there were many questions about the data.  The statement and 
recommendations were confusing.  In addition the research and statistical data were not 
clearly understood.  Therefore the DNP student submitted a request for assistance from 
the Nursing Research Team.  In July of 2009, the DNP student met with the Assistant 
Vice President (AVP) of nursing research in the Center for Professional Excellence in 
research.  After examination of the BESt the AVP concluded that the data analysis was 
incorrect and therefore the recommendations may not be accurate.  She recommended the 
entire process be repeated and the BESt be recreated prior to any policy change (M. Huth, 
personal communication, July, 2009).  At that time it became the focus of the DNP 
student to develop a new BESt for the confirmation of NGT/OGT placement starting 
from the beginning of the developmental process. 
 The AVP of nursing research suggested the DNP student contact the original 
BESt development team to inquire if there was any interest in assisting with the new 
project.  Members were contacted by electronic mail and of the fifteen original members, 
ten declined involvement, four members responded positively, and one had left the 
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institution and could not be contacted.  In addition, the AVP of nursing research 
suggested the DNP student invite one of the EBP mentors to be part of the team. 
At Cincinnati Children’s the role of the EBP mentor is to foster the development 
of an evidence-based approach to clinical practice on the unit level and to guide nursing 
staff by educating and role modeling the use of evidence to advance best practice at the 
point of care (Cincinnati Children’s Hospital Medical Center, 2010b).  The EBP mentor 
is an advanced practice nurse practitioner who has completed extended training through a 
week-long immersion program in EBP.  The mentor’s purpose is to collaborate with an 
interdisciplinary unit-based team to facilitate the use of evidence in clinical decision-
making (Cincinnati Children’s Hospital Medical Center, 2010b).  The EBP mentor is part 
of Cincinnati Children’s Center for Professional Excellence (CPE) whose purpose is to 
support excellence in nursing.  The CPE is divided into education, research, and quality.  
The vision of the research division is to “to establish expertise in research and evidence-
based practice that improves the health and well-being of children and families” 
(Cincinnati Children’s Hospital Medical Center, 2010a).  The mission is to “advance the 
process and practice of research and evidence-based practice in the care of children and 
families” (Cincinnati Children’s Hospital Medical Center, 2010a).  Mentors are available 
to staff as support with projects related to evidence-based practice.  In this case the DNP 
student was the project leader and facilitator of the overall BESt development process. 
Resources 
In BESt development it is helpful to assess available resources and current 
barriers for the project.  Resources for this project included financial and administrative 
support from organizational stakeholders.  In addition, staff support in the way of 
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personnel, equipment, and supplies were also available.  Barriers to the success of the 
project were also considered.  Future implementation would require training and 
development, equipment, and supplies, all which require financial support.  Other 
potential barriers included staff resistance to change, lack of commitment from nurses, 
and the lack of time needed to learn a new process.  Regulatory barriers related to the 
monitoring and reporting of bedside testing also posed a threat. 
Literature Review and Appraisal 
The literature review was conducted in order to uncover information, which will 
answer the clinical questions.  Search strategies aimed to identify literature pertaining to 
any method of NGT insertion.  The search was conducted using Ovid database including 
Medline, CINAHL, and Cochrane Database for Systematic Reviews.  Search filters used 
years 1996 to present and was limited to humans, the English language, and the highest 
quality evidence, such as systematic reviews.  Key words used were children and 
nasogastric tube, NG tube, gastric aspirate, auscultation and nasogastric, x- ray 
verification of NG tube, morphological distances, and nasoenteral measurement 
(Appendix C).  Additional articles were identified from a hand search of the reference 
lists of the reviewed articles.  
Multiple studies were reviewed and 24 met the inclusion criteria for the project 
based on the clinical questions.  In addition to clinical relevance, other factors that were 
considered for inclusion were the overall merit of the study, and applicability of the 
subjects.  Literature review tools served as a guide for individual study review.  
A hierarchy of evidence, or level of evidence, provided guidance about the types 
of evidence that would provide reliable answers to the clinical questions (Melnyk & 
Fineout-Overholt, 2011).  There are various hierarchies depending on the type of clinical 
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question being asked.  For example for intervention questions such as the questions for 
this project, the hierarchy of evidence ranks a well done systematic review or meta-
analysis the highest level of evidence.   
Critical Appraisal 
The levels of evidence as adopted by Cincinnati Children’s are based on the 
LEGEND system that stands for “Let Evidence Guide Every Decision” (Clark, Burkett, 
& Stanko-Lopp, 2009).  The LEGEND system is a comprehensive evaluation system that 
was developed through a review of the literature, which examines multiple evidence 
evaluation systems.  Evaluation systems were evaluated by criteria, which assessed if the 
system was systematic, functional, generalizable, user-friendly, and validated.  From the 
evaluation criteria, the LEGEND system was created and consists of six tools; glossary, 
table of evidence levels, algorithm, evidence appraisal forms, grading the body of 
evidence, and judging the strength of a recommendation (Clark, Burkett, & Stanko-Lopp, 
2009).  
Following the LEGEND system, literature is assigned a quality level or grade 
from one to five with one being highest-level studies.  Level 1 studies are systematic 
reviews or meta-analysis, Level 2 include randomized controlled trials, Level 3 studies 
are non-randomized controlled, quasi-experimental, or cohort studies.  The fourth level 
studies are well-designed non-experimental studies that are descriptive or case studies, 
and Level 5 studies are expert opinion, case reports and clinical examples (Cincinnati 
Children’s Hospital Medical Center, 2011).  Another component of leveling is the 
subjective classification by the reviewer of the study as either “a” or “b” based on the 
quality of the study.  An “a” level study is one that is considered by the reviewer to be a 
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good quality study with appropriate methods and sufficient sample size.  Whereas a “b” 
study in comparison would be a lesser quality study with a less adequate sample size, or 
lacking validity, reliability, or applicability.  This quality assignment is subjective from 
the reviewer’s standpoint and allows for flexibility and individual judgment.  For 
example, a study, which uses a cohort design and has a small sample size and 
demonstrated some applicability, might be given a grade of 3b.  Appendix D shows the 
table of evidence levels. 
Evidence appraisal forms guide the researcher through the questions of validity, 
reliability and applicability (Clark, Burkett, & Stanko-Lopp, 2009).  Each form is specific 
to each type of study design.  Most of the studies reviewed for this project were 
descriptive with a few cohort studies and only one randomized controlled trial.  While 
cohort studies represent a stronger study design, there were very few available related to 
the ethical concern of having an experimental group with a misplaced tube and a control 
group with a correctly placed tube.  The appraisal tools used for randomized controlled 
studies; descriptive studies and cohort studies are presented in Appendices E, F and G 
respectively.   
The literature for the clinical questions was reviewed with two main objectives in 
mind.  The first was to identify literature, which pertained to current practice of 
measurement with the NEX method and verification by auscultation.  The second was to 
identify other methods of NGT or OGT measurement and verification.  Findings were 
organized according to the method examined: radiography, auscultation, measurement, 
aspiration, and other methods. 
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Radiography.  In the review of the literature, no one best method of NGT/OGT 
placement was identified however; radiography, or x-ray, is cited as the gold standard for 
verification by multiple researchers and is used as a benchmark to test other methods 
(Metheny et al., 1994a; Metheny & Stewart 2002; Nyquist, Sorell, & Ewald, 2005; Peter 
& Gill, 2008; Ellett & Beckstrand, 1999; Westhus, 2004).  However, a landmark study 
that established radiography as the gold standard could not be identified.  Still, 
radiography is the gold standard for tube verification because it is the only method in 
which the entire course of the tube can actually be visualized.  In addition, there is a very 
small error rate associated with x-ray that is attributed to human error, related to misread 
films. 
Even though radiography is the gold standard, it is expensive especially when the 
frequency of verification is considered.  Furthermore, the exact risk of radiation exposure 
from x-rays obtained for tube verification is unknown but any radiation exposure is 
concerning in young children (Neuman et al., 1995).  The literature summary for 
radiography is presented in Table 2. 
Auscultation.  Auscultation pertains to the method of using a ten or twelve 
milliliter syringe and instilling one to two millimeters of air into the tube while 
auscultating over the stomach with a stethoscope (Hockenberry & Wilson, 2007).   
Although widely used by pediatric nurses, the accuracy of auscultation to verify 
placement in the stomach has been shown to have poor reliability and is not 
recommended as a sole verification method (Ellett & Beckstrand, 1999; Metheny, 
McSweeney, Werhle, & Wiersma, 1990; Neumann et al., 1995).  The high error rate with 
this method is related to the inability to differentiate sounds from the esophagus,  
      
 
  
Table 2  
Studies assessing radiography 
Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Ellett & 
Beckstrand, 
1999 
 Descriptive n=46 Pediatric 
hospital 
Less than  
19 yr. 
requiring 
enteral 
nutrition or 
decom-
pression by 
NG, OG, or 
NJ 
Verification of 
existing tube 
placement by 
submersion in 
water, auscultation 
and aspiration and 
pH testing 
compared to x-ray 
Tube 
placement in 
intended 
location 
Tube placement 
errors occurred in 
43.5 % of tubes. 
Children who 
were comatose or 
semi-comatose, 
were inactive, had 
swallowing 
problems or had 
argyle tubes were 
more likely to 
have errors 
Yes 4b 
Metheny, et 
al., 1994A 
Prospective 
cohort 
n=605 Hospital 18-94 yr. Compared tube 
verification with 
pH, using pH paper 
or pH meter with x-
ray. Determine 
mean pH of gastric 
and intestine 
 Impact of 
feedings on 
pH, H2 
blockers or 
PPI on tube 
placement in 
intended 
location 
pH > 6 indicated 
gastric placement. 
Meter and pH 
paper moth 
effective. 
Medications 
resulted in 
slightly higher pH 
values. 
Teens and 
Adults 
3a 
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Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Metheny 
&Stewart, 
2002 
Prospective 
cohort 
n=80 Hospital 18-87 yr. 
with NG 
tubes in place 
receiving 
continuous 
feedings 
Appearance for bile 
stain or no bile 
stain, pH, pepsin, 
trypsin, 
The extent to 
which 
appearance, 
pH, pepsin, 
trypsin and 
bilirubin of 
aspirated 
could 
differentiate 
between 
placement in 
the stomach 
and intestine 
during 
continuous 
feedings 
Bile stained 
aspirates are more 
likely to be from 
the intestine. 
Aspirate of ph < 6 
less likely that the 
tube is in the 
stomach. Mean 
pepsin was higher 
in gastric. Mean 
trypsin was 
higher in 
intestinal. 
Bilirubin was 
higher in intestine 
Teens and 
Adults 
3a 
Nyquist et 
al., 2005 
Descriptive n=60, 
2970 
obser-
vations 
Hospital Infants born 
at gestational 
age 24-42 
weeks 
Tested aspirate for 
litmus reaction. 
To determine 
the use of 
litmus paper 
tests for 
assessment of 
aspirates in 
infants. 
High ratio of 
positive litmus 
reactions in all 
ages. 
Infants 4a 
Peter & 
Gill, 2008 
Descriptive n=1527 Hospital Unknown Evaluated aspirates 
for presence and pH 
following new 
guideline. 
To evaluate 
practice 
changes. 
Aspirates were 
obtained for 97% 
of all tests, pH 
was < 5.5 for 
84% 
Yes 5 
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Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Westhus, 
2004 
Descriptive n=56 Hospital 
ICU 
Birth-14yr. 
with NG, OG 
or NJ 
Examined ph, 
appearance, pepsin 
and trypsin of 
aspirate and got x-
ray 
To what 
extent pH, 
appearance, 
pepsin and 
trypsin 
predict 
placement. 
Impact of 
acid 
suppression. 
 Yes 4b 
2
3
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stomach, intestine, or lungs (Metheny et al., 1990).  In a descriptive study, Ellett and 
Beckstrand (1999) studied hospitalized children with existing enteral tubes and compared 
submersion method, auscultation, aspiration, and pH testing to x-ray.  Auscultation of a 
sound over the left upper quadrant was found to have a positive predictive value of 20% 
(assessed to be incorrectly placed by auscultation and found to be incorrectly placed on x-
ray) and a negative predictive value of 63.6% (tubes assessed to be correctly placed by 
auscultation and found to be correctly placed on x-ray) (Ellett & Beckstrand, 1999).  
Metheney et al. (1990) also observed the auscultation method.  In this study nurses were 
asked to classify recorded sounds which were generated by air insufflations through 
feeding tubes.  The overall average percent of correct classification was 34.4%.  
Auscultation over the left upper quadrant were classified correct 41.6 % of the time, F 
(3/111) = 2.94, p=.0362.  In a prospective cohort study, Newman et al. (1995) compared 
auscultation to x-ray and found that sensitivity (percentage of tubes incorrectly placed on 
x-ray and also incorrectly placed on auscultation) was high at 98.3%, but specificity 
(correctly placed on x-ray and determined correctly placed on auscultation) was only 
6.3% with a positive predictive value (assessed to be incorrectly placed by auscultation  
and found to be incorrectly placed on x-ray) of 79.5% and a negative predictive value 
(tubes assessed to be correctly placed by auscultation and found to be correctly placed on 
x-ray) of only 50% (p=0.31).  These studies support the idea that auscultation alone is not 
an accurate method of NGT or OGT placement.  A summary of the literature for 
auscultation is presented in Table 3. 
 Tube measurement.  Proper tube measurement also plays an important role in a 
successful NGT/OGT placement.  Several studies have examined the NEX method to 
 
 
Table 3 
Studies assessing auscultation 
Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
Outcomes 
Applic-
ability 
Evidence 
level 
Ellett & 
Beckstrand, 
1999 
Descriptive n=46 Pediatric 
hospital 
< Than 19 yr. 
requiring 
enteral nutrition 
or 
decompression 
by NG, OG or 
NJ 
Verification of 
existing tube 
placement by 
submersion in 
water, 
auscultation 
and aspiration 
and pH testing 
compared to 
x-ray 
Tube 
placement in 
intended 
location  
Tube placement 
errors occurred 
in 43.5 % of 
tubes. Children 
who were 
comatose or 
semi-comatose, 
were inactive, 
had swallowing 
problems or had 
argyle tubes 
were more 
likely to have 
errors 
Yes 4b 
Metheny, et 
al., 1990 
Descriptive n=123 Hospital 21 yr. & older Compared 
audio recorded 
sounds from 5 
sites 
Ability to 
classify 
sounds 
Overall 
classification 
only 34 % 
Yes 4a 
 
 
Newman et 
al., 1995 
Cohort n=28 Hospital 36-92 years old 
  
Compared pH 
and 
auscultation to 
x –ray 
To determine 
cut off for pH 
of gastric 
aspirates. 
Reliability of 
auscultation. 
Recommended 
pH cut off of  < 
4. Auscultation 
alone was not 
effective. 
Adults 3b 
2
5
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estimate tube length.  The NEX method is done by measuring from the tip of the nose, to 
the tip of the ear lobe, to the tip of the xiphoid (Gallaher, Cashwell, Hall, Lowe, & 
Ciszek, 1993).  Although NEX is a relatively simple method its reliability has been 
questioned.  Weibly, Adamson, Clinkscales, Curran, & Bramson (1987) compared the 
NEX method to a method using a point mid-way between the termination of the xiphoid 
and the umbilicus (NEMU) then compared both to x-ray.  The NEX method had an 
incorrect placement rate of 55.6 percent and the NEMU method had an incorrect rate of 
39.3 percent (Weibly et al., 1987).  In a RCT, Klaussner, Luke and Scalzo (2002) 
examined the variability of the NEX method compared to a graphic method based on the 
patient’s height.  Tubes were placed according to one of the methods and then compared 
to x-ray.  Results showed that tubes placed with the NEX methods showed twice as much 
variability in placement off the center of the stomach compared to the graphic method 
(1.31cm [SD3.39] versus -1.12 cm [SD1.36] (Klaussner, Luke, & Scalzo, 2002).  This 
study suggests that alternate methods of measuring may be more accurate.  Gallaher and 
colleagues (1993) studied minimal insertion lengths of OGT’s in premature infants and 
compared estimated lengths with NEX to x-ray.  Results showed that of 171 x-rays, eight 
(4.7%) revealed the OGT to be low, 57 (33.3%) revealed the OGT to be high and 106 
(62%) revealed the OGT to be in adequate position (Gallaher et al., 1993). 
The poor accuracy of the NEX method to determine placement prompts the need 
to examine other methods to determine proper tube length.  Early work was done by 
Strobal, Byrne, Ament, and Euler (1979) who looked at correlating esophageal lengths in 
children with height.  Esophageal length was measured manometrically and compared to  
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age, surface area, and height to determine if there was a correlation with any of these 
values.  From these measurements an equation was developed for calculation of 
esophageal length.  These measurements were then tested by comparing the calculated 
length to those obtained using the esophageal length.  The correlation coefficients of 
esophageal length with age and surface area were significant (P< 0.001) with r=0.9444 
and 0.963 (oral) and r= 0.01 and 0.876 (nasal).  This study was important as it provided a 
reliable calculation of esophageal length based on the patient’s height.  
Putnam and Orenstein (1991) also looked at esophageal lengths to determine 
whether crown rump length (CRL) and distance from the suprasternal notch to the 
anterior superior iliac spine are correlated with esophageal length.  Additionally, they 
examined whether there was a mathematical reliability between distance from the nose to 
the mid-right atrial (NTMRA) shadow and the nose to the diaphragm (NTD).  A 
correlation with CRL was identified.  The NTD and NTMRA measurements correlated 
best with height NTD=0.4 (height)= 5.2, with r=0.96, and SEM = 1.1; and NTMRA =0.2 
(height)=4.8 with r=0.96 and SEM =0.98. CRL also correlated will with NTD and 
NTMRA with NTD =0.47 (CRL) =0.57, r=0.93 and SEM =1.4.  The distance from 
suprasternal notch to anterior superior iliac spine correlated less well, with NTD=0.9 
(SIS) =1.3, r=0.82, and SEM =2.3; and NTMRA =0.7 (SIS) =1.2, r =0.84, SEM=1.9.   
Ellett, Beckstrand, Welch, Dye, & Games (1992) tested Stroebel et al.’s (1979) 
regression equations by comparing esophageal lengths by manometry to the regression 
equations.  Results indicated that the oral reference equation predicts esophageal length 
in children less than four years old.  The nasally-referenced equation appeared 
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systematically biased and performed poorly but was probably related to a small sample 
size (Ellett et al., 1992). 
Beckstrand, Ellett, & McDaniel (2007) also considered the work of Stroebel et al. 
(1979), Putnam and Orenstein (1991) and others to examine how well morphological 
distances perform as predictors of the internal distance to the targeted position for the 
tube tip in the stomach.  In a large sample of children aged 2 weeks to 19 years, the 
predicted distances were compared to endoscopic and manometric distances.  The age-
specific prediction equations were able to predict the internal distance to place all pores 
(openings at the tip) of the tube in the body of the stomach 98.8 % of children aged 6 
months to 100 months of age and 96.5% in children older than 100 months old.  A 
summary of the literature for tube measurement is presented in Table 4. 
Aspirate testing methods.  In addition to auscultation and measurement, there is 
considerable discussion in the literature about methods, which rely on examination of 
gastric aspirate, which includes pH, enzymes, and visual inspection. 
An early multi-site study by Metheny, Reed, Wiersma, McSweeney, Werhle & 
Clark (1993) evaluated the extent to which pH aspirates from feeding tubes can be used 
to differentiate between gastric and intestinal tube placement and gastric and respiratory 
tube placement.  They performed pH readings with a pH meter within five minutes of 
obtaining an abdominal radiograph.  Of the 794 pH meter readings 405 were from 
nasogastric tubes and 389 were from nasointestinal tubes.  They reported 85% of the 405 
reading were between 0 and 6.0 while over 87% of the 389 intestinal aspirates were 
greater than 6.0.  In addition, four aspirates from feeding tubes inadvertently place in the  
      
 
 
Table 4 
Studies assessing tube measurement 
Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Beckstrand, 
et al., 2007 
Descriptive n=498 Hospital 2 weeks to 
19 yr. 
undergoing 
endoscopy 
or 
manometry 
Morphological 
distances 
compared to 
endoscopy 
and/or 
manometry 
Internal 
distance to 
the stomach 
for 
nasogastric 
and 
orogastric 
tube 
insertion. 
Age specific 
methods 
predict 
distance to 
the body of 
the stomach 
in 98.8% of 
children. 
NEXU was 
nest best 
predictor. 
Yes 4a 
Ellett, et al., 
1992 
Descriptive n=107 Hospital 1 mo – 
14.4 yr. 
undergoing 
esophageal 
manometry 
Compared 
esophageal 
length by 
manometry to 
Strobel’s 
regression 
equations 
Esophageal 
length 
Strobel’s oral 
reference 
equation 
predicts EL 
in children 
less than 4 yr. 
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Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Gallaher, et 
al., 1993 
Cohort n=171 Neonatal 
Intensive 
care 
23-31 weeks 
post 
conceptual 
age who had 
OGT and x-
ray 
Length of 
gavage tube 
insertion via 
NEX compared 
to x-ray 
Minimal 
insertion 
length 
Predicted 
length was 62 
% accurate 
Neonates 4a 
Klasner, et 
al., 2002 
RCT n=44 Hospital 
emergency 
room 
6 mo. – 18 
yr. 
NEX to graphic 
method based 
on height 
NEX and 
graphic 
method to 
determine 
tube in 
intended 
location 
Graphic 
method 
resulted in 
tubes being 
placed closer 
to the center 
of the 
stomach. 
Yes 2b 
Putnam, et 
al., 1991 
Descriptive n=65 unknown 3 days – 10 
yr. 
Measured 
height, crown-
rump length, 
and distance 
from the 
suprasternal 
notch to the left 
anterior 
superior iliac 
spine 
Correlation 
of crown-
rump length 
with 
esophageal 
length 
Crown-rump 
lengths 
correlated 
will with 
esophageal 
length 
yes 4a 
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Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Strobel, et 
al., 1979 
Descriptive n=119 unknown 3 weeks – 
235 months 
Measured 
esophageal 
length, and 
correlated with 
age, height and 
surface area. 
Generated 
equation of 
esophageal 
length 
Correlation 
of 
esophageal 
lengths with 
height 
Age, surface 
area and 
height were 
all 
significantly 
correlated. 
For children 
less than 120 
months there 
was less 
variability. 
Esophageal 
length best 
correlates 
with height 
Yes 4b 
Weibley, et 
al., 1987 
Descriptive n=30 unknown 28 to 36 
weeks 
gestational 
age at birth 
Placed NG tube 
NEX, or nose, 
ear & point 
mid-way 
between the 
termination of 
the xiphoid and 
the umbilicus 
confirmed with 
x-ray  
Compare 
two methods 
of placement 
NEX 
compared to 
x-ray showed 
55.6 % 
incorrect 
placement. 
Nose ear and 
mid-way 
showed 39.3 
% placements 
Premature 
infants 
4a 
3
1
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respiratory tract had pH values greater than 6.5.  They concluded that gastric placement 
was distinguished from intestinal placement (p<. 0001), and from respiratory placement.  
In the same study by Ellett and Beckstrand (1999) that looked at auscultation, pH 
testing was also compared to x-ray.  Using a pH cut off of < 4 the positive predictive 
value was 0%  (assessed to be incorrectly placed by pH and found to be incorrectly 
placed on x-ray) and a negative predictive value of 85% (tubes assessed to be correctly 
placed by pH and found to be correctly placed on x-ray).  In an attempt to compare 
gastric and intestinal aspirates, Metheny et al, (1999b) described pH, visual appearance, 
as well as the enzymes pepsin, trypsin and bilirubin.  pH samples were obtained from 
feeding tubes of infants and sent to a research laboratory for testing.  Although mean 
gastric and intestinal aspirates could not be compared because of the low number of 
intestinal aspirates that were obtained, findings from this study were important because it 
suggested that gastric pH was not significantly higher with feedings, 4.66 versus 3.92; 
p=.07.  The study reported a mean gastric pH of 4.32.   
Metheny, Stewart, Smith, Diebold & Clouse (1999a), also examined pH and 
bilirubin as predictors of placement.  They compared mean pH and bilirubin of aspirates 
from intestine, stomach, and lungs from newly inserted small-bore feeding tubes.  pH was 
measured with a pH meter and bilirubin content was measured spectrophotometrically. 
Results of the testing were compared with tube location determined by radiography.  
Mean pH levels in the lung (7.73) and intestine (7.35) were significantly higher than the 
mean pH level in the stomach (3.90; p<.001).  In addition, bilirubin levels in the stomach 
and lung were significantly higher than the intestine.  This study suggested that a low pH 
of < 5 is a strong indicator of gastric placement.  Findings were similar in a 2002 study 
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by Metheny & Stewart who reported the mean pH was 5.7 for gastric and 6.6 for 
intestinal making a pH of < 6 a statistically significant indicator of gastric placement.  In 
addition the mean pepsin concentration was higher in gastric aspirate (188ug/ml) than 
intestinal aspirate (38.5ug/ml) (t+7.98, p<.001).  For bilirubin, the mean concentration 
was higher in intestinal aspirates (7.9 mg/dl) than in gastric (0.4 mg/dl) (t= -11.26, 
p<.001).  Gharpure, Meert, Sarnaik, and Metheny (2000) confirmed the findings of 
Metheny & Stewart (2002) and found that a pH of > 6 has high negative predictive value 
for intestinal position and a bilirubin of > 5 has high positive predictive value.  Westhaus 
(2004) also looked at pH as predictor of tube location.  This study confirmed that mean 
gastric pH was significantly lower (4.1) than mean intestinal pH7.5 (t=-4.0; <.001).  
One study examined the ability to classify aspirates by visual inspection. 
Metheny, Reed, Burglund and Werhle (1994b) used photographs of aspirates from the 
stomach or intestine to test clinician’s ability to classify aspirates.  The subjects were able 
to identify 81 % of the gastric aspirates correctly but only 64 percent of the intestinal 
aspirates were correctly identified.  
At least one study compared pH testing using pH paper versus a pH meter. 
Metheny et al. (1994a) reported that pH paper was a reliable method of pH testing.  In 
addition it was reported that a pH of < 6 indicated gastric placement.  
 Ellett et al. (2005) also observed pH and bilirubin levels and compared the 
methods to x-ray.  Aspirates were collected and measured with a pH meter.  This study 
was important for several reasons.  First, they reported that pH of <5 had a positive 
predictive value (tubes assessed to be incorrectly placed outside the stomach) of 25%, 
and a negative predictive value (tubes shown to be correctly placed in the stomach) of 
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85% in confirming gastric placement.  Like previous studies, they reported that mean pH 
levels were not significantly different for patients receiving feedings.  This study also 
found that acid-inhibiting medication did not significantly affect pH.  The summary of 
the literature for aspirate methods is presented in Table 5. 
Other methods.  In addition to x-ray, auscultation, aspiration, other methods of 
placement confirmation are described in the literature.  Carbon dioxide (CO2)  
measurement is another method of testing for NG/OG tube placement.  Typically a 
capnograph monitor is used to measure the concentration of the partial pressure of CO2. 
A low level of CO2 would indicate placement outside the respiratory tract (Ellett et al., 
2005).  In the same study by Ellett and colleagues (2005) the method of CO2 
measurement was compared to x-ray.  CO2 measurement was done by attaching the open 
end of a gastric tube to a capnograph monitor and two repeated measurements were 
taken.  The values in all 72 cases were well below the established cut off of < 15 for 
adults suggesting CO2 measurement is reliable in children.  However, equipment can be 
costly and may not be practical for bedside use. 
Recently, use of a magnet tracking system to determine NG tube placement has 
been described in the literature (Bercik et al., 2005).  Bercik and colleagues (2005) 
compared tubes placed with a magnet system to those placed by x ray.  A small magnet 
was attached to the end of an NG tube and the position was monitored using an external 
sensor.  The study reported the accuracy of the magnet tracking system to be 100% 
compared with fluoroscopy.  A summary for the literature for other methods is presented 
in Table 6. 
      
 
 
Table 5 
Studies assessing aspirate 
Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Metheny et 
al., 1993 
Cohort n=794 Multi-site 
hospital 
18 to 94 years Measured 
pH of 
aspirates at 
time of 
placement 
compared to 
x-ray 
The extent to 
which pH can 
determine 
tube 
placement 
Gastric 
placement 
distinguished 
from 
intestinal and 
respiratory 
placement. 
Mean gastric 
pH 3.52 
Yes, 
Teens 
and 
Adults 
3a 
Ellett & 
Beckstrand, 
1999 
Descriptive n=46 Pediatric 
hospital 
< Than 19 yr. 
requiring 
enteral nutrition 
or 
decompression 
by NG, OG or 
NJ 
Verification 
of existing 
tube 
placement by 
submersion 
in water, 
auscultation 
and 
aspiration 
and pH 
testing 
compared to 
x-ray 
Tube 
placement in 
intended 
location 
Tube 
placement 
errors 43.5 % 
of tubes. 
Children 
comatose or 
semi 
comatose, 
inactive, had 
swallowing 
problems or 
had argyle 
tubes were 
more likely to 
have errors. 
 
Yes, 
children 
4b 
3
5
 
 
 
Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Metheny, et 
al., 1999B 
Descriptive n=90 Neonatal 
intensive 
care 
4 days –182 
days old 
Compared 
pH, pepsin, 
trypsin, 
bilirubin and 
visual 
appearance 
determine 
mean pH of 
gastric an 
intestinal 
aspirates in 
fed and 
unfed 
pH , pepsin, 
trypsin and 
bile levels to 
compare  
gastric and 
intestinal tube 
aspirates 
Mean gastric 
and intestinal 
could not be 
compared due 
to low 
number of 
intestinal 
aspirates.. 
Gastric pH 
was higher 
with feedings. 
Mean gastric 
ph 4.3 
Neonates 4a 
Metheny, et 
al., 1999A 
Descriptive n=587 Unknown 14 – 93 yr. with 
newly placed 
feeding tubes 
verified by x 
ray 
Compared 
mean pH and 
bilirubin of 
aspirates 
from 
intestine, 
stomach and 
lungs 
The extent to 
which pH and 
bilirubin can 
determine 
tube 
placement 
Mean 
bilirubin of  < 
5 confirmed 
gastric 
placement. 
pH cut off of 
5 confirmed 
gastric 
placement 
 
 
 
 
 
 
 
Yes, 
Teens 
and 
Adults 
4a 3
6
 
 
 
Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Garpure, et 
al., 2000 
Descriptive n=96 Pediatric 
ICU 
8 days – 19 yr. Color, pH, 
bilirubin, 
pepsin, and 
trypsin 
compared to 
x-ray 
Color, pH, 
bilirubin, 
pepsin, and 
trypsin to 
verify tube 
placement in 
intended 
location 
pH of >6 had 
high negative 
predictive 
value. Overall 
efficiency 
best for clear 
yellow, 
pepsin < 20 
94%, trypsin 
> 50 94%. No 
difference for 
H2 blockers 
or PPI 
Yes, 
children 
4a 
Metheny & 
Stewart, 
2002 
Prospective 
cohort 
n=80 Hospital 18-87 yr. with 
NG tubes in 
place receiving 
continuous 
feedings 
Appearance 
for bile stain 
or no bile 
stain, pH, 
pepsin, & 
trypsin 
The extent to 
which 
appearance, 
pH, pepsin, 
trypsin and 
bilirubin of 
aspirated 
could 
differentiate 
between 
placement in 
the stomach 
and intestine 
during 
continuous 
feedings 
Bile stained 
aspirates are 
more likely to 
be from the 
intestine. 
Aspirate of 
pH <6 less 
likely tube in 
the stomach. 
Mean pepsin 
higher in 
gastric. Mean 
trypsin & 
bilirubin 
higher 
intestine.  
Yes, 
Teens 
and 
Adults 
3a 3
7
 
 
 
Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Westhus, 
2004 
Descriptive n=56 Hospital 
intensive 
care 
Birth to 14 yr. 
with NG, OG or 
NJ 
Examined 
ph, 
appearance, 
pepsin and 
trypsin of 
aspirate and 
got x-ray 
To what 
extent pH, 
appearance, 
pepsin & 
trypsin predict 
placement. 
Impact of acid 
suppression. 
 Yes, 
children 
4b 
Westhus, 
2004 
Descriptive n=56 Hospital 
intensive 
care 
Birth to 14 yr. 
with NG, OG or 
NJ 
Examined  
ph, 
appearance, 
pepsin and 
trypsin of 
aspirate and 
got x-ray 
To what 
extent pH, 
appearance, 
pepsin and 
trypsin predict 
placement. 
Impact of acid 
suppression. 
 Yes, 
children 
4b 
Metheny, et 
al., 1994B 
Descriptive n=880 Hospital Not given Classified 
photographs 
of aspirated 
from 
stomach or 
intestine 
Ability to 
classify 
aspirates 
Able to 
identify 81% 
of gastric 
aspirated and 
64 percent of 
intestinal 
aspirates 
 
 
 
 
 
 
Yes 4a 
3
8
 
 
 
Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Metheny, et 
al., 1994A 
Prospective 
cohort 
n=605 Hospital 18-94 yr. Compared 
tube 
verification 
with pH, 
using pH 
paper or pH 
meter with x-
ray. 
Determine 
mean pH of 
gastric and 
intestine 
Impact of 
feedings on 
pH, H2 
blockers or 
PPI on tube 
placement in 
intended 
location 
pH > 6 
indicated 
gastric 
placement. 
Meter and pH 
paper moth 
effective. 
Medications 
resulted in 
slightly higher 
pH values. 
Yes, 
Teens 
and 
Adults 
3a 
Ellet, et al., 
2005 
Cohort n=72 Hospital 3 days-7 yr. 
with gastric 
tube in place 
Verification 
of tube 
placement by 
CO2 and 
aspirating 
contents and 
measuring 
pH and 
bilirubin 
compared to 
x-ray 
pH and CO2 
of aspirate of 
correctly 
placed tubes 
pH of 5 
correctly 
predicted 
tubes in the 
stomach 85%, 
bilirubin 
failed to 
indentify the 
two misplaced 
tubes 
Yes, 
children 
3a 
3
9
 
      
 
 
Table 6 
Other confirmation methods 
Study 
Citation 
Study 
Design 
Sample 
Size 
Setting Sample 
Population 
Independent 
Variable/ 
Intervention 
Dependent 
variable/ 
outcome 
measure 
Results/ 
outcomes 
Applic-
ability 
Evidence 
level 
Bercik, 
et al., 
2005 
 
Descriptive n=22 Healthy 
subjects 
26-42 yr. Used magnet 
tracking system to 
determine NG tube 
tip and compared to 
manometry 
Accuracy of NG 
tube placement 
with magnet-
tracking system 
Magnet tracking 
system was 
accurate in NG 
tube tip 
localization 
No 4b 
Ellet, et 
al., 2005 
Cohort n=72 Hospital 3 days- 7 
yr. with 
gastric tube 
in place 
Verification of tube 
placement by CO2 
and aspirating 
contents and 
measuring pH and 
bilirubin compared 
to x-ray 
pH and CO2 of 
aspirate of 
correctly placed 
tubes 
pH of 5 
correctly 
predicted tubes 
in the stomach 
85%, bilirubin 
failed to identify 
the two 
misplaced tubes 
Yes 3a 
  
4
0
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Expert opinion.  Throughout the development of the guideline experts in the 
field were consulted.  One expert, Dr. Philip Putnam, Director of Endoscopy Services at 
Cincinnati Children’s was consulted regarding his opinion related to a reasonable cut off 
for pH which would determine gastric placement.  Dr. Putnam has been a board certified 
pediatrician for 24 years and a board certified pediatric gastroenterologist for 17 years. 
He specializes in the area of gastro esophageal reflux in children. In the literature, 
recommended pH cut off varied from 4 to 6.5.  Lack of consensus in the literature made 
Dr. Putnam’s opinion a valued part of this project.  Based on his experience he felt a cut 
off pH of 5 would be valid (P. Putnam, personal communication, June, 2011) 
Patient and family preferences.  Patient values are an important part of EBP 
(Sackett et al, 2000).  When dealing with children the needs of the family must also be 
considered therefore the opinions of parents whose children need NG or OG tubes were 
explored.  
During the two week period in November 2008 when NGT/OGT insertion 
required radiographic verification, the Gastrointestinal Unit director received negative 
feedback from several families (A. Longo, personal communication, November, 2008).  
Comments mostly pertained to the inconvenience of having to leave the hospital unit to 
obtain an x-ray and the wait times.  The cost of repeated x-rays was also mentioned as a 
concern by a few of the parents.   
 Synthesis of the Evidence 
Having performed the review of the literature (ROL) as well as leveling and 
grading of each piece of evidence, it is important to grade the entire body of evidence as 
it pertains to the clinical question.  The method utilized at Cincinnati Children’s is 
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presented in Appendix I.  The body of evidence for NGT or OGT tube insertion was 
evaluated and determined to have a grade of “moderate”.  This was supported by the 
number of studies, the corresponding quality of the studies, and the consistency of the 
results.  The evidence would not be considered “high” level evidence because of the low 
number of available RCT’s.   
Following the Iowa Model for EBP development, the next step was to synthesize 
the research.  From the ROL for NGT/OGT placement several key ideas were 
summarized.  First, radiologic verification of NGT/OGT is the gold standard.  However, 
non-radiologic verification methods provide an accurate alternative in patients who are 
not considered at high risk for aspiration.  Patients who are at high risk include those who 
have neurologic impairment and other conditions such as those patients who are 
obtunded, sedated, unconscious, critically ill, have a reduced gag reflux, or have static 
encephalopathy (Ellett & Beckstrand, 1999; Metheny et al., 1994a;  Phang, Marsh, 
Barlows, & Schwartz, 2004).   
Second, bedside pH testing of gastric aspirate can be used to confirm placement 
(Ellett et al., 2005; Metheny et al., 1993; Metheny et al., 1999a; Metheny et al., 1999b; 
Metheny & Stewart, 2002).  The mean pH levels were summarized in Table 7.  The mean 
pH of gastric aspirate is statistically lower (higher acidity) compared to intestinal aspirate 
mean pH (Metheny et al., 1999a).  Mean pH of respiratory aspirate from the 
tracheobronchial tree or plural space is statistically higher than gastric aspirate pH 
(Metheny et al., 1999a).  In addition, pH testing can be accurately done with either pH 
paper or pH meter (Ellet et al., 2005; Metheny et al., 1994a; Westhus, 2004).  Mean  
      
 
 
Table 7  
Comparison of mean pH by site 
Summary of findings for 
Gastric, Intestinal and 
Respiratory pH Study  
Sample Gastric Aspirate pH 
mean (SD) 
Intestinal Aspirate pH 
mean (SD) 
Respiratory Aspirate pH 
mean (SD) 
Ellett, 2005 3 days -7 years  
n=72  
4.5 (1.4)  No data  No data  
Metheny, 1999b Neonates  
n=90  
4.32 (0.20)  7.80  No data  
Metheny, 2002  18 years-87 years  
n=80  
5.7 (0.1) *  6.6 (0.1)*  No data  
Metheny , 1999a 14yrs-adult  
n=587  
3.90 (0.15)  7.35 (0.06)  7.73 (0.04) 
(tracheobronchial tree)  
Metheny, 1993  18yrs-94 yrs  
n=794  
3.52 (2.02)  7.05 (1.26)  No data  
Phang, 2004  25yrs-92yrs  
n=181  
4.8 (2.3)  
Acid 43up  
5.0 (2.3)  
No acid  
4.0 (2.5)  
7.1 (1.0)  
Acid 43up  
7.2+-1.0  
No acid  
6.7+-1.1  
No data  
Metheny, 1994a n=800  3.52 (2.02)  
Acid  
3.84 (2.06)  
No acid  
3.12 (1.90)  
7.05 (1.26)  7.38 (0.59) (plural space)  
Westhus, 2004  Birth-14yrs  
n=56  
4.1 (0.32)  7.5 (0.33)  No data  
Garpure, 2000  8 days -19yrs  
n=96  
4.1  
Fed 5.0  
Not fed 4.0  
6.8  
Fed 6.6  
Not fed7.0  
No data  
4
3
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values for gastric aspirate are not significantly different when patients are fed or fasting 
(Metheny & Stewart, 2002; Metheny, 1999a) nor are mean values for aspirates  
significantly different when patients are on or off acid suppression medications (Ellett et 
al., 2005; Metheny et al., 1994a).  
Other bedside testing methods are available but have limitations.  For example, 
auscultation has been shown to have poor reliability and is not recommended as a sole 
verification method (Ellett & Beckstrand, 1999; Metheny & Stewart, 2002, Metheny et 
al., 1990; Neumann et al., 1995).  In addition, visual inspection of aspirate has not been 
shown to be a reliable sole method of verification; however, it may have some use when 
done in conjunction with pH testing (Gharpure et al., 2000; Metheny & Stewart, 2002; 
Metheny et al., 1999b, Metheny et al., 1994a; Metheny et al., 1994b; Phang et al., 2004; 
Westhaus, 2004).  Aspirate testing of enzyme levels for bilirubin, pepsin, and trypsin also 
provide an alternate method of verification, but it is limited to laboratory assessment 
(Ellett et al., 2005; Gharpure et al., 2000; Metheny & Stewart, 2002; Metheny et al., 1999 
a; Westhaus, 2004).  While CO2 monitoring provides an alternate method of verification, 
it requires a capnograph monitor to determine incorrect tube placement (Ellett et al, 
2005).  Magnet tracking systems have also been shown to be accurate but the clinical 
feasibility of their use needs further investigation (Bercik et al., 2005). 
Finally, there is moderate evidence that improving the accuracy of NGT or OGT length 
prior to insertion will enhance the precision of successful tube placement (Beckstrand et 
al., 2007; Ellett et al., 1992; Gallaher et al., 1993; Klaussner et al, 2002; Putnam & 
Orenstein, 1991; Stroebel et al., 1979). While morphological measurement using NEX or 
NEMU can be used, prediction equation tables are more accurate in predicting tube 
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length (Beckstrand et al., 2007, Elle et al., 1992; Klaussner et al, 2002; Putnam & 
Orenstein, 1991; Stroebel et al., 1979) (Appendix I) 
Recommendations for Practice  
 Following a thorough review and critique of the literature, recommendations for 
practice were developed with input from the EBP mentor and the original BESt team 
members.  Furthermore, in order to determine the strength of each recommendation the 
evaluation tool Judging the Strength of a Recommendation was used.  The judgment of 
the recommendation is made based on a process, which considers the critically appraised 
evidence, clinical experience and other dimensions (Cincinnati Children’s Hospital 
Medical Center, 2011).  Dimensions include grade of the body of evidence, safety, health 
benefit, burden of adherence, cost effectiveness, and directness of evidence as it relates to 
the recommendation (Appendix J).  Based on the evidence evaluated for the insertion of 
NGT/OGT’s several practice change recommendations can be made:  
1. It is recommended that radiologic verification be used to determine NGT/OGT 
placement in pediatric patients who are determined by clinical judgment to be at high risk 
of aspiration or when non-radiologic methods are not feasible (aspirate cannot be 
obtained), or results of non-radiologic methods are unclear.  Pediatric patients at risk for 
incorrect tube placement include those who have neurologic impairment and other 
conditions which may increase the difficulty of safe, effective tube placement and include 
patients who are obtunded, sedated, unconscious, critically ill and those with reduced gag 
reflex or static encephalopathy (Metheny et al., 1994a; Phang et al., 2004; Ellett & 
Beckstrand, 1999).  An order from a provider with prescriptive authority is required for 
radiological verification. 
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2. It is recommended that non-radiological verification methods be used to 
confirm placement of NGT/OGT in pediatric patients who are not considered at high risk 
for aspiration using the following method: Aspirate pH testing using pH paper or pH 
meter with aspirate pH cut off of <5 to confirm gastric placement (Ellett et al., 2005; 
Metheny et al., 1999b; Metheny & Stewart, 2002; Metheny et al, 1999a; Metheny et al, 
1993).  An order from a provider with prescriptive authority is required for tube 
placement and for pH testing.  
3. It is recommended that NGT/OGT length be predicted as follows:  
For children >2 weeks, age-related height-based (ARHB) methods are more accurate than 
other morphological measures such as nose-ear-xiphoid (NEX) or nose-ear-mid-xiphoid-
umbilicus (NEMU) in predicting tube length and should be calculated using prediction 
equation tables (Appendix J) (Beckstrand et al., 2007; Ellett et al. 1992; Klaussner et al., 
2002; Putnam & Orenstein, 1991; Stroebel et al., 1979).  Calculations will be computed 
automatically by the electronic medical record system. 
For neonates less than 2 weeks of age, patients with short stature, or if unable to 
obtain an accurate height, use morphological measurements such as NEX or NEMU 
(Beckstrand et al, 2007).  Short stature is defined as a standing height more than 2 
standard deviations (SDs) below the mean (or below the 2.5 percentile) for sex (Cohen, 
Rogol, Deal et al., 2008).  
  Measurement using the NEMU method for tube length prediction versus the NEX 
method is slightly more reliable for tube length prediction (Beckstrand et al., 2007; 
Gallaher et al, 1993; Weibly et al., 1987).  Tube length should be marked at the nare for 
NGT, or corner of the mouth for OGT with indelible permanent marker and document 
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amount of tube remaining (external visible length) (EVL) outside the patient in the 
patient record (Weibly et al, 1987).   
The next step was to present the recommendations for NGT/OGT insertion 
utilizing the BESt format.  However in order to examine the applicability of the project, it 
is helpful to first perform a SWOT analysis.  A SWOT analysis pertains to the 
identification of potential or actual Strengths, Weaknesses, Opportunities and Threats to a 
new program or guideline (Berkowitz, 2006).  Each area was explored as it pertained to 
the development and future implementation of a BESt for NGT/OGT insertion. 
Strengths.  The strengths of a project consider what benefits the proposed change 
might have.  For this project, the biggest strength was the opportunity to change practice 
to reflect current literature.  In addition, the project provided nursing staff with the 
satisfaction of knowing practice is current and supports safety standards.  
Weaknesses.  The weaknesses of the project addressed potential barriers that were 
encountered.  One barrier related to the regulations for bedside testing.  Currently routine 
bedside testing of gastric pH was not being done at Cincinnati Children’s and its 
implementation could be problematic related to government regulations regarding 
bedside testing and stringent monitoring and record keeping.  Failure to maintain proper 
documentation could result in sanctions from governing agencies. 
Opportunities.  Opportunities for a project identify what benefits the 
implementation of change has to offer.  In this case, development and implementation of 
a guideline for NGT/OGT insertion resulted in safer outcomes and improved quality care 
for patients and contributed to cost savings as well as improved patient and staff 
satisfaction.  
 
48 
Threats.  Threats to a project or program addresses what obstacles might be faced 
or what difficulties might be encountered.  For this project, potential threats included 
difficulties related to future implementation of the recommendations including staff 
resistance to change, lack of commitment from nurses, and the lack of time it takes to 
learn a new process.  
Analysis of utility.  Prior to development of a BESt for NGT/OGT insertion an 
analysis of utility should be performed.  An analysis of utility serves to examine the 
findings from the literature and determine applicably to the project, feasibility of 
development, benefits, resources, and potential costs as it relates to the population of 
interest.  The analysis of utility for this project is outlined in Appendix K. 
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III. Implementation 
Population of Interest 
 The population of interest was patients admitted to Cincinnati Children’s who 
required a NGT/OGT.  The population was limited to patients aged 2-weeks to adult. 
This population was chosen because it is representative of the population found in the 
literature review.  
Practice Setting  
 Project implementation took place at Cincinnati Children’s. This setting was 
chosen because of the culture of safety and the desire to find an evidence-based method 
of NGT/OGT placement.  In addition, institutional support and the availability of 
resources made Cincinnati Children’s an appropriate choice for the location of the 
project. 
Identification of Resources 
  When implementing a change in practice it is vital to identify resources which 
will be important for success of the project.  Key personnel for this project included: the 
EBP mentor, the Evidence-Based Decision Making (EBDM) Program Administrator and 
the BESt review team who are part of the Anderson Center for Health Systems 
Excellence.  
Ethical and Legal 
 While the project did not require institutional review board approval, there were 
necessary permissions that were obtained. In order to use Cincinnati Children’s name in 
the final paper, agency permission was obtained from the Vice President of Patient 
Services at Cincinnati Children’s (Appendix L).  Written permission to use the Iowa 
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Model was also obtained via electronic mail from the University of Iowa Hospitals and 
Clinics (Appendix M).  In addition, written permission to use Beckstrand’s (2007) tube 
length prediction equation tables was obtained via electronic mail (Appendix N). 
Process for Implementation 
Implementation of this project consisted of publication of the BESt and involved 
two separate processes.  First, recommendations were published August 22, 2011 
according to the BESt development process at Cincinnati Children’s and posted on the 
James M. Anderson Center for Health Systems Excellence website.  Publication of the 
BESt allowed Cincinnati Children’s, as well as, any provider to acquire the updated 
guideline.  Subsequently, the BESt was submitted to the National Guideline 
Clearinghouse and published online March 28, 2012.  
The project was implemented following the steps of the Iowa Model.  The steps 
of the Iowa Model were used to guide the specific activities of the project and are 
presented in figure 2.  The objectives, correlating activities, accountability of team 
members, and completion dates are presented in an implementation plan (Appendix O).    
Following development of the recommendations the next step was to arrange the 
information from each step of the Iowa Model into the BESt format according to the 
BESt User Checklist (Appendix P).  The BESt template was also used as a guide and 
provided a systematic arrangement in which the information was summarized and 
organized.  In May 2011 the process was completed and the document was ready for 
review.
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Figure 2 
Iowa Model for this project 
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IV. Project Evaluation 
 For the purpose of this project, evaluation pertains to the process of BESt review 
for publication.  Two separate processes were utilized and will be described separately; 
the process of BESt publication internally and externally on the Cincinnati Children’s 
James M. Anderson Center for Health Systems Excellence website, and the process of 
publication on the National Guideline Clearinghouse (NGC) website. 
Cincinnati Children’s Hospital Medical Center Publication 
Following preparation of the BESt according to the BESt template a conflict of 
interest form was submitted (Appendix Q).  The purpose of this form was to disclose any 
financial or intellectual conflicts of interests.  There were no conflicts related to this 
project.  The BESt was then submitted electronically to the Evidence-based Decision 
Making (EBDM) Program Administrator.  The role of the EBDM Program Administrator 
is to serve as a facilitator of the review and publication process of BESt’s.  The Program 
Administrator then forwarded the document to two independent reviewers, who are 
trained in EBDM, who evaluated the BESt against a defined set of quality criteria 
(Appendix R).  In June 2011 the BESt was returned to the DNP student for editing and 
revisions.  After editing, the document was resubmitted in July 2011 and passed the final 
review.  On August 22, 2011 the BESt for Confirmation of NGT/OGT Placement was 
published internally on Cincinnati Children’s intranet and externally on the Cincinnati 
Children’s James M. Anderson Center for Health Systems Excellence web page. The 
final Cincinnati Children’s BESt is presented in Appendix S. 
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National Guideline Clearinghouse Publication 
 Upon approval and publication both internally and externally at Cincinnati 
Children’s the process for publication on the National Guideline Clearinghouse (NGC) 
was initiated.  The NGC has a well-defined process of approving submitted guidelines for 
publication, which is outlined on the NGC web site.  A guideline submission checklist 
provided step-by-step instructions for submission (Appendix T).  Criteria for inclusion 
was a document which provided an explanation as to what type of guideline documents 
are accepted by the NGC (Appendix U).  The BESt was eligible for consideration under 
the second criterion which states that the “guideline was produced under the auspices of a 
health care organization” (U.S. Department of Health and Human Services Agency for 
Health Research and Quality, 2012e).  The BESt was prepared for submission following 
the required guideline attributes (Appendix V).  In August, 2011, with the assistance of 
Cincinnati Children’s EBDM Program administrator, the BESt was submitted to the NCG 
electronically in a word document in the BESt format.  The following day, submission 
verification was received from NGC via electronic mail.  Approximately two weeks later, 
notification was received via electronic mail stating the submission met the inclusion 
criteria and that the document would be abstracted into the NGC format according to the 
guideline attributes.  Communication from the NGC also stated that there was a backlog 
of about 250 documents and it was possible it would take four to six months before 
abstraction of the BESt was complete.  In March of 2012 notification was received via 
electronic mail from NGC that abstraction of the BESt was complete and the guideline 
was published on the agency’s web page March 28, 2012 (Appendix W). 
Evaluation of Impact 
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One way health care organizations can work to improve safety and patient 
outcomes is through development of clinical practice guidelines (CPG’s).  According to 
Peter and Gill (2008) CPG’s “are designed to improve the quality of health care, reduce 
practice variation, and reduce unnecessary, harmful, or ineffective interventions, at an 
acceptable cost”.  CPG’s can be developed using an EBP model (Gray, 2001) and BESt’s 
are one way to organize the findings.  Clinical practice guidelines are designed “to 
improve the quality of health care, reduce practice variation and reduce unnecessary 
harmful or ineffective interventions at an acceptable cost” (Peter and Gill, 2008).  NGC 
employs the definition of clinical practice guideline developed by the IOM that “clinical 
practice guidelines are systematically developed statements to assist practitioner and 
patient decisions about appropriate health care for specific clinical circumstances”(U.S. 
Department of Health and Human Services Agency for Health Research and Quality, 
2012d).     
Publication of the BESt within the Cincinnati Children’s institution provided the 
groundwork for future policy revision and subsequent practice change.  Through 
publication on the NGC, the BESt is a nationally published resource for others who care 
for children needing NGT/OGT insertion.
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V. Discussion 
Outcomes and Future Steps 
The desired outcomes for this clinical project were met and are evidenced by the 
publication of the BESt statement both internally and externally by Cincinnati Children’s, 
and by the NGC.  Notification of publication of the BESt on Cincinnati Children’s web 
site was sent to the key team members via electronic mail.  
Although goals for this project were met through publication of the BESt and a 
considerable amount of time has lapsed since the start of the project, more work is still 
needed.  This project is clinically significant because it will become the framework for 
which a pilot or test of change will be designed and implemented, and will guide policy 
revision and widespread incorporation into practice.  
According to the Iowa Model, if there is significant evidence to support a change 
in practice the change should be piloted.  Piloting is the next step in the EBP process and 
serves to identify the feasibility and effectiveness of a guideline (Titler et al., 2001).  The 
steps of the pilot process involves (a) selecting outcomes, (b) collecting baseline data, (c) 
developing a written guideline, (d) testing the guideline in a small setting, (e) evaluating 
the process and outcome of the trial,  and (f) modifying the guideline based on process 
and outcome data.  A pilot could be conducted on one unit of a multiunit institution. 
Based on the results of the pilot and determination of feasibility, a decision should 
be made whether or not to adopt the change into practice.  If a change is implemented on 
a large scale it will be important to monitor and analyze structure, process, and outcome 
data.  This information will include insight from staff, patients and families, as well as 
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environmental and cost factors.  Finally, following the Iowa Model, the results of the 
EBP project should be disseminated.  
Facilitators and Barriers  
The most important reason for implementing EBP is that it leads to the highest 
quality care and high quality care is synonymous with safety.  The Institute of Medicine 
(IOM) defines safety as “the prevention of harm to patients” (Institute of Medicine, 2004, 
p 5) and considers patient safety “indistinguishable from the delivery of quality health 
care” (Institute of Medicine (IOM), 2004, p 5).  Therefore, it is important to build a 
delivery system that prevents errors, learns from the errors that do occur; and is built on a 
culture of safety (Institute of Medicine, 2004).  A culture of safety can be defined as an 
“integrated pattern of individual and organizational behavior, based upon shared beliefs 
and values, that continuously seeks to minimize patient harm that may result from the 
processes of care delivery” (IOM, 2004, p 174).  Misplaced NGT/OGT’s are errors from 
which there are lessons to be learned and should become the focus of future quality 
improvement projects.  Organizations such as Cincinnati Children’s that strongly support 
a culture of safety use EBP to improve outcomes.  Bartelt et al (2011) reported that the 
support of administrators, clinical leaders, expert clinicians and practice decision makers 
is necessary for effective EBP.  Other concepts, which support implementation of EBP, 
are leadership, EBP teams, methods of group supervision, and modeling and mentoring 
(Bartelt et al, 2011). Cincinnati Children’s organizational commitment to safety and 
quality improvement contributed to success of this project.  
Although the organization supported a culture of safety and utilization of quality 
measures, barriers still existed throughout the project.  Barriers to using research 
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evidence in nursing practice has been described in the literature and categorized as 
individual or organizational (Brady & Lewin, 2007; McCleary & Brown, 2003).  
Individual barriers include lack of time for EBP activities, difficulty understanding 
findings, lack of authority to implement findings, being unaware of research and being 
blocked in implementing findings by nurses or physicians.  Organizational barriers 
include lack of access to technology, time demands for clinical work, lack of peer or 
administrative support, and an organizational culture that does not value EBP activities.  
In several studies where nurses were surveyed regarding the perceived barriers to using 
research in practice, organizational support was found to be the most important factor, 
specifically, insufficient time (Retsas, 2000; Van Patter Gale & Schaffer, 2009; McCleary 
& Brown, 2003).  Barriers for this project were consistent with those reported in the 
literature.  
Organizational barriers presented the biggest challenge for this project 
specifically the lack of dedicated project time and level of priority for the project.  While 
stakeholders verbalized support of the project, little support in the way of dedicated 
project time was given to team members.  Team members verbalized time constraints and 
were not always able to give the project priority.  Because of these time constraints, there 
were difficulties in scheduling meetings in a timely fashion.  Although administrators 
supported the project there was a lack of urgency for its completion.  This lack of 
urgency resulted in a considerable time lag from start to finish of the project.  
One way to aid in implementation of evidence is to apply a model to support 
clinical change.  Application of Rogers (2003) Diffusion of Innovations theory can be 
applied to aid in implementation and adoption of EBP.  Rogers defines diffusion as “the 
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process by which an innovation is communicated through certain channels over time 
among the members of a social system” (Rogers, 2003, p11).  While most of his work 
was concerned with the diffusion of innovations to individuals, Rogers recognized that 
many innovations are adopted also by organizations.  Often an individual cannot adopt a 
new idea until an organization has adopted the change.  The innovation process for 
organizations consists of five stages: agenda setting, matching, redefining or 
restructuring, clarifying and routinizing (Rogers, 2003).  Agenda setting occurs when an 
organizational problem is defined.  Matching is the stage which a problem from the 
organization agenda is fit with an innovation and this match is planned and designed.  
Redefining/restructuring occurs when the innovation is re-invented to accommodate the 
organizations needs and structure more closely and when the organizations structure is 
modified to fit with the innovation.  Clarifying occurs when the innovation is put into 
more widespread use and finally, routinization occurs when the innovation has become 
incorporated into the regular activities of the organization.  
The barriers encountered in this project can be addressed by considering Rogers 
stage of matching.  During this stage in the innovation process is when “conceptual 
matching occurs to see how well they fit” with the goals of an organization (Rogers, 
2003, p 423).  One explanation for the time lag and lack of dedicated time for the project 
is the possibility that the innovation is mismatched with the problem.  The situation 
surrounding NGT/OGT tube placement may no longer be a problem or a priority for the 
organization, or the problem has low importance in the context of organization.  
Therefore prior to proceeding with the remaining three stages of Rogers’s theory which 
relate to implementation, it may be necessary to revisit the level of priority the project 
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holds with the stakeholders and reconsider whether the change is an appropriate match 
with the organization. 
Final Summary 
 EBP is key to the delivery of the highest quality healthcare and for ensuring best 
patient outcomes (Melynk & Fineout-Overholt, 2011).  An EBP model such as The Iowa 
Model can be used to guide the Doctorate of Nursing Practice (DNP) through 
implementation of an EBP change project. The Iowa Model was used to guide the 
development of a Best Evidence statement (BESt) for confirmation of NGT/OGT 
placement, which was published both at an institutional level as well as on a public 
guideline database. 
In 2006 the American Association of Colleges in Nursing published The 
Essentials of Doctoral Education for the Advanced Practice Nurse.  These eight essentials 
outline the elements of doctoral education.  One of the foundational outcome essentials 
pertains to clinical scholarship and analytical methods for evidence-based practice 
(American Association of Colleges of Nursing, 2006).  The DNP is prepared to use 
advance nursing knowledge to create EBP guidelines, such as BESt‘s, through translation 
of new science, application, and evaluation.  
 Rogers (2003) emphasized the value of a champion and the role a champion can 
play in innovation of new idea in an organization.  The advanced practice nurse 
practitioner that provides direct patient care is in a unique position to evaluate current 
practice and use EBP to directly improve patient care outcomes. Advanced practice 
nurses’ who have earned a DNP degree are considered key facilitators’, or champions’, of 
EBP.  As a champion of EBP, the DNP serves as a role model, coach, and mentor of EBP 
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with others.  In conclusion, the DNP is integral in closing the evidence to practice gap by 
being a champion for EBP and therefore contributing to improved high quality, safe 
outcomes at the systems and organizational level. 
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Appendix B 
Stakeholders/Team Members 
Team Member Role 
Cincinnati Children’s senior nursing 
administrative team 
Upper level administrative support 
Unit Director Support/leadership 
EBP mentor Key team player/leader/partner 
Nursing staff Key team player/leader/partner 
Education coordinator  Key team player/leader/partner 
Best review team Advisory 
Medical staff Support/leadership 
Nurse Practice council Advisory 
Radiology administration Advisory 
Lab administrator Advisory 
Nurse Practitioner/DNP student Leader/Partner 
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Appendix C 
Databases Searched and Data Abstraction Table 
Keyword Used Database/Source  
Used  
# of Hits 
Listed Reviewed Used 
Children, and 
nasogastric tube,  
CINAHL, 
Cochrane Database 
65 18 13 
NG tube,  CINAHL 59 20 13 
Gastric aspirate,  CINAHL 34 22 8 
Auscultation  and 
nasogastric 
CINAHL 13 3 3 
X-ray verification 
of NG tube,  
CINAHL 2 1 1 
Morphological 
distances,  
CINAHL 3 3 3 
Nasoenteral and 
measurement,  
CINAHL 22 10 8 
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Appendix D 
Summary of Evidence Levels 
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4a 
4b 
 
5a 
5b 
Prevalence 
1a 
1b 
        
2a 
2b 
 
3a 
3b 
4a 
4b 
 
5a 
5b 
Meaning / KAB
+
  
1a 
1b 
   
2a 
2b  
 
3a 
3b 
   
4a 
4b 
 
 
5a 
5b 
Economic Analysis 
Decision Analysis 
1a 
1b 
     
2a 
2b 
     
4a 
4b 
 
5a 
5b 
 * a = good quality study   * b = lesser quality study       
 + 
CCT = Controlled Clinical Trial; KAB = Knowledge, Attitudes, and Beliefs; RCT = Randomized Controlled Trial 
 
Shaded boxes indicate study design may not be appropriate or commonly used for the domain of the clinical question. 
 
Development for this table is based on:  
1. Phillips, et al: Oxford Centre for Evidence-based Medicine Levels of Evidence, 2001. Last accessed Nov 14, 2007 from HUhttp://www.cebm.net/index.aspx?o=1025UH. 
2. Fineout-Overholt and Johnston: Teaching EBP: asking searchable, answerable clinical questions. Worldviews Evid Based Nurs, 2(3): 157-60, 2005. 
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Appendix H 
Grading of the Body of Evidence 
   
LEGEND 
Let Evidence Guide Every New Decision 
Grading the Body of Evidence 
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Grade Method 
High 
Sufficient number of high quality studies with consistent* results. 
Step 1 
(see worksheet to summarize 
the body of evidence) 
NUMBER OF STUDIES QUALITY OF STUDIES* CONSISTENCY OF RESULTS* 
1 1a NA 
2+ 1a or 2a Yes 
5+ 1a, 2a, or 3a Yes 
5+ 1a, 1b, 2a, or 2b Yes 
Step 2  
(if the studies didn’t fit neatly 
into a box in step 1) 
 multiple studies, unless large effect and very clinically important 
 strong designs for answering the question addressed 
 clinically important and consistent results with minor exceptions at most 
 free of any significant doubts about validity (generalizability, bias, design flaws) 
 adequate statistical power (including studies showing no difference) 
Confirmation Step Further research is unlikely to change our confidence in the answer to the clinical question. 
Moderate 
Multiple studies of lesser quality or with inconsistent results, or a single well-done study. 
Step 1 
(see worksheet to summarize 
the body of evidence) 
NUMBER OF STUDIES QUALITY OF STUDIES* CONSISTENCY OF RESULTS* 
1 2a NA 
3+ 1, 2, 3; a or b Yes 
5+ 1, 2, 3, 4; a or b Yes 
Step 2  
(if the studies didn’t fit neatly 
into a box in step 1) 
Either 
 multiple studies 
 strong designs for answering the question addressed 
 some uncertainty due to either 
 validity threats (generalizability, bias, design flaws or adequacy of statistical power), or 
 inconsistency 
Or 
 multiple studies 
 weaker designs for answering the question addressed 
 consistent results with minor exceptions at most 
Confirmation Step 
Further research is likely to have an important impact on our confidence in the precision of the answer to the 
clinical question, and may even change the answer itself. 
Low 
Local opinion, case reports, case studies, and general reviews. 
Step 1 
(see worksheet to summarize 
the body of evidence) 
NUMBER OF STUDIES QUALITY OF STUDIES CONSISTENCY OF OPINION 
1+ or local opinion 
5 
Clear local consensus 
Step 2  
(if the studies didn’t fit neatly 
into a box in step 1) 
 local consensus is clear 
 health professional opinion is the only relevant published information 
Confirmation Step 
There is local and/or published consensus, but no research, to answer the clinical question. 
Further research is very likely to have an important impact on the answer. 
Grade 
Not 
Assignable 
Insufficient design or execution, too few studies, and inconsistent results 
Step 1 
NUMBER OF STUDIES QUALITY OF STUDIES* CONSISTENCY OF RESULTS* 
 0+  3b, 4b  No 
Step 2  
(if the studies didn’t fit neatly 
into a box in step 1) 
 studies have not been done, or 
 published studies are seriously flawed and/or  
 published studies give inconsistent results 
Confirmation Step There is insufficient evidence and lack of consensus to answer the clinical question. 
*Note:  When there is both high and low quality evidence and the results are inconsistent: 
• Disregard lower quality evidence if the lower quality evidence is inconsistent with all higher quality evidence. 
• Avoid disregarding lower quality evidence when inconsistency is at multiple quality levels, because bias could be introduced when determining which evidence 
to disregard. 
 
Some of the concepts for this development are based on: Atkins et al: Grading quality of evidence and strength of recommendations. BMJ, 328(7454): 1490, 2004; 
Briss et al: Developing an evidence-based Guide to Community Preventive Services--methods. The Task Force on Community Preventive Services. Am J Prev Med, 
18(1 Suppl): 35-43, 2000; and Greer et el: A practical approach to evidence grading. Jt Comm J Qual Improv, 26(12): 700-12, 2000. 
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Judging the Strength of  a Recommendation 
 
 
 
LEGEND 
Let Evidence Guide Every New Decision 
Judging the Strength of a Recommendation 
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James M. Anderson Center for Health Systems Excellence | Center for Professional Excellence | Edward L. Pratt Research Library 
Evidence-Based Decision Making LEGEND Resources – http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/resources.htm  
Project Title:  Date:  
In determining the strength of a recommendation, the development group makes a considered judgment. 
The judgment is made explicit in a consensus process which considers critically appraised evidence, clinical experience, 
and other dimensions.  The development group will consider what the relative weight each dimension listed below 
contributes when determining the strength of a recommendation. 
Reflecting on your answers to the dimensions below and given that more answers to the left of the scales* indicates 
support for a stronger recommendation, complete one of the sentences below to judge the strength of this 
recommendation. 
*(Note that for negative recommendations, the left/right logic may be reversed for one or more dimensions.) 
 It is strongly recommended that… 
 It is recommended that… 
 There is insufficient evidence and a lack of 
consensus to make a recommendation on… 
 
 
Dimensions 
1. Grade of the Body of Evidence  High grade evidence  Moderate grade 
evidence 
 Low grade evidence 
2. Safety / Harm  Has minimal 
adverse effects 
 Has moderate adverse 
effects 
 Has serious adverse 
effects 
3. Health benefit to patient  
(direct benefit) 
 Has significant 
health benefit 
 Has moderate health 
benefit 
 Has minimal health 
benefit 
4. Burden on patient to adhere to 
recommendation 
(cost, hassle, discomfort, pain, 
motivation, ability to adhere, time) 
 Low burden of 
adherence 
 Unable to determine 
burden of adherence 
 High burden of 
adherence 
5. Cost-effectiveness to healthcare 
system  
(balance of cost / savings of resources, 
staff time, and supplies based on 
published studies or onsite analysis) 
 Cost-effective to 
healthcare system 
 Inconclusive economic 
effects 
 Not cost-effective 
to healthcare 
system 
6. Directness 
(the extent to which the body of 
evidence directly answers the clinical 
question [population/problem, 
intervention, comparison, outcome]) 
 Evidence directly 
relates to 
recommendation 
for this target 
population. 
 There is some concern 
about the directness of 
evidence as it relates 
to the recommen-
dation for this target 
population. 
 Evidence only 
indirectly relates to 
recommendation 
for this target 
population. 
7. Impact on morbidity/mortality or 
quality of life 
 High impact on 
morbidity/mortality 
or quality of life 
 Medium impact on 
morbidity/mortality or 
quality of life 
 Low impact on 
morbidity/mortality 
or quality of life 
 
Some of the concepts for this development based on: 
Guyatt: Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians 
task force. Chest, 129(1): 174-81, 2006; Harbour: A new system for grading recommendations in evidence based guidelines. BMJ, 323(7308): 334-6, 
2001; and Steinberg: Evidence based? Caveat emptor! Health Aff (Millwood), 24(1): 80-92, 2005. 
     
 
 
Appendix K 
Analysis of Utility 
Finding(s) Intervention Fit 
with 
Setting 
Fit with 
Sample 
Feasibility of 
Implementation 
Benefits Risks Resources 
Needed 
Potential 
Costs 
Metheny et 
al., 1994a; 
Phang et al., 
2004;  
Ellett & 
Beckstrand, 
1999  
X-ray Good 
fit 
Similar 
population 
Very feasible. Safest way to 
determine 
practice in 
high risk 
patients 
None- is 
current 
practice 
Staff support, 
administrative 
support 
None 
Ellett et al., 
2005;  
 
Metheny et 
al., 1999b;  
 
 Metheny & 
Stewart, 
2002;   
 
Metheny et 
al, 1999a ;  
 
Metheny et 
al, 1993 
 
pH testing Good 
fit 
Similar 
population 
Somewhat 
feasible. Will 
require education 
and change in 
practice. 
More accurate 
determination 
of placement 
in patients not 
considered 
high risk. 
May be 
difficult to 
maintain 
compliance 
with 
required 
regulations  
Financial, staff 
support, 
administrative 
support, 
Equipment, 
education 
Equipment, 
training,  
9
1
 
 
 
Finding(s) Intervention Fit 
with 
Setting 
Fit with 
Sample 
Feasibility of 
Implementation 
Benefits Risks Resources 
Needed 
Potential 
Costs 
Beckstrand 
et al., 2007; 
Ellett et al. 
1992;   
Klausner et 
al., 2002; 
Putnam & 
Orenstein, 
1991;   
Strobel et 
al., 1979 
Measurement 
using ARHB 
methods 
Good 
fit 
Similar 
population 
Very feasible. 
Will require 
modifications to 
documentation 
system and staff 
education.  
Will provide a 
more accurate 
length 
prediction. 
System 
error 
Information 
services, 
education, staff 
support, 
administrative 
support 
TBD 
 
  
9
2
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Permission to Reproduce the Iowa Model 
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Permission to use Prediction Equation Table 
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Appendix O 
Implementation Plan  
Objectives Activities  Person(s) 
Accountable 
Completion 
Date 
1. Identification of 
the practice 
questions or 
“triggers” 
Prioritization of topics: 
brainstorming about current 
problem and overall goals of 
project.  
Sherri Sievers  
 
9/2008 
Elicit input of stakeholders Sherri Sievers 12/2008 
2. Priority of the 
topic 
Gain support of stakeholders Sherri Sievers 2/2009-5/2009 
Set focus and limits of project Sherri Sievers  
Barbara Giambra 
7/2009 
3. Forming a team Identify potential members Sherri Sievers 
Barbara Giambra 
7/2009 
Invite identified members Sherri Sievers 8/2009 
Select team leader Sherri Sievers 8/2009 
4. Assembling 
relevant research 
and related 
literature 
Electronic search and retrieval 
of literature 
Sherri Sievers 
Barbara Giambra 
Libriarian 
8/2009 
5. Critique and 
synthesis of 
research 
 
 
Complete scientific merit 
review 
Sherri Sievers  
Barbara Giambra 
10/2009 
Synthesize best evidence and  
develop recommendations 
Sherri Sievers 
Barbara Giambra 
1/2010 
6. Determine if 
there is significant 
research to guide 
practice 
Development of BESt 
statement. 
Sherri Sievers 
Barbara Giambra 
1/2010-5/2011 
Publish BESt on Cincinnati 
Children’s website 
 8/2011 
Publish BESt on 
AHRQ/Guidelines.gov 
 5/2012 
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Appendix Q 
Conflict of Interest 
 
Evidence-Based	Care	Guideline	or	Best	Evidence	Statement	
	
Conflict	of	Interest	Disclosure	
(CoI)	
	
	
Copyright	©	2005,	2008,	2011–2012	Cincinnati	Children's	Hospital	Medical	Center;	all	rights	reserved.	
James	M.	Anderson	Center	for	Health	Systems	Excellence	|	Evidence-Based	Decision	Making	–	http://groups/ce/NewEBC/EBCMain.htm	 	 Page	1	of	1	
	
In	accordance	with	IOM	(Institute	of	Medicine)	and	AGREE	(Appraisal	of	Guidelines	for	Research	and	Evaluation)	criteria,	Development	Team	
Members	and	key	professional	support	staff	must	declare	whether	they	have	any	conflict	of	interest.		Any	situation	that	would	or	would	be	
perceived	as	capable	of	influencing	the	decision	for	any	recommendation	within	the	evidence	work	is	considered	a	conflict.	
															
Name:	 	
	
	 Credentials	(e.g.	RN,	MD):	 	
Division:	 	
	 	
Title	or	Topic	of	Guideline	or	Best	Evidence	Statement:	 	
	 	
Role	on	Proposal:	 		Team	Member	
		Key	Professional	Support	Staff	(e.g.	members	of	Evidence	Collaboration)	
	 	 	 	
Please	check	all	that	apply:	
	 	 	
A. 	 No	significant	financial	interests*	exist	related	to	this	Evidence-Based	Care	Guideline	(EBCG)	or	Best	Evidence	Statement	(BESt)	
development	or	revision	which	would	require	a	disclosure.	
B. 	 No	significant	intellectual	interests	exist	related	to	this	Evidence-Based	Care	Guideline	(EBCG)	or	Best	Evidence	Statement	(BESt)	
C. 	 A	disclosure	is	required.		I	hereby	disclose	the	following	significant	interest(s):		(Check	all	that	apply)	
	 Salary	or	other	payment	for	services			(e.g.,	consulting	fees	or	honoraria,	royalties)	
	 Equity	interests			(e.g.,	stocks,	stock	options,	or	other	ownership	interests)	
	 Other	significant	financial	interests	that	could	possibly	affect	or	be	perceived	to	affect	the	specific	EBCG	or	BESt	development,	
implementation	or	reporting	activities	
	 Intellectual	interests			(e.g.,	patents,	copyrights,	authorship	of	article	or	research	involvement	that	bears	directly	on	recommendations,	influence	
of	expertise)	
		Other	interests	pertinent	to	the	potential	scope	of	these	activities	(e.g.,	non-commercial,	institutional,	and	patient/public	activities)	
	 	
If	C	is	checked,	you	must	attach	a	signed,	written	statement	(in	an	envelope	marked	“Confidential”)	identifying	the	business	entity	involved,	the	
nature/type	of	the	interest,	and	the	amount	of	the	interest	that	is	related	to	the	specific	EBCG	or	BESt	development,	implementation	or	
reporting	activities.	
	
			I	attest	that	I	have	listed	all	relevant	financial,	intellectual,	professional,	and	personal	conflicts	that	have	occurred	within	the	previous	12	
months	and	that	I	will	immediately	update	this	information	if	changes	occur.	
By	checking	this	box,	I	agree	to	the	terms	of	this	electronic	disclosure.					
	 Signature	(please	type	your	signed	name):			 	
	 Date:	 	
Send	completed	form	via	e-mail	to	EBDMinfo@cchmc.org.	
	
	
	
*	Financial	Interest	does	not	include:	
1. Salary,	royalties,	or	other	remuneration	received	directly	from	CCHMC.	
2. Equity	interests	that,	when	aggregated	for	the	Covered	Individual	and	his/her	family,	do	not	exceed	$5,000	in	fair	market	value	and	do	not	represent	a	five	
(5)	percent	or	greater	ownership	interest	in	a	single	entity.	
3. Salary,	royalties,	or	other	payments	that,	when	aggregated	for	the	Covered	Individual	and	his/her	Family	are	not	expected	to	exceed	$5,000	in	the	prior	or	
next	twelve	(12)	months.	
4. Interests	arising	solely	by	reason	of	investment	by	mutual,	pension,	or	other	institutional	investment	funds	over	which	the	Covered	Individual	does	not	
exercise	control.	
5. Royalties	for	publishing	scholarly	works	or	other	writings.	
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Reviewer Checklist 
  
Best	Evidence	Statement			(BESt)	
Reviewer	Checklist	
for	evaluating	readiness	for	posting	of	BESt	
	
Copyright	©	2011-2012	Cincinnati	Children's	Hospital	Medical	Center;	all	rights	reserved.																					April	25,	2012	
CCHMC	Evidence	Collaboration:	 James	M.	Anderson	Center	for	Health	Systems	Excellence	|	Center	for	Professional	Excellence	|	Edward	L.	Pratt	Research	Library	
Evidence-Based	Decision	Making	(EBDM)	LEGEND	Resources	–	http://www.cincinnatichildrens.org/evidence	 	 	 Page	1	of	1		
BESt	Title:	
	
	
Met	 Not	Met	 	
	 	 Clinical	question	is	complete	and	presented	in	PICO	format.	
Comment:	 	
	 	 Target	Population	is	complete,	including	Inclusion	&	Exclusion	Criteria.	
Comment:	 	
	 	 Recommendation(s)	is	(are)	adequately	specific	and	unambiguous.		
Comment:	 	
	 	 Recommendation(s)	is	(are)	easily	identifiable	and	begin(s)	with	the	appropriate	recommendation	
phrase	to	signify	the	strength	of	the	recommendation.	
Comment:	 	
	 	 Discussion/Synthesis	of	Evidence	relates	to	the	recommendation(s).	
Comment:	 	
	 	 References/Citations	are	present	and	explicitly	associated	with	the	recommendation(s).	
Comment:	 	
	 	 All	citations	have	been	assigned	a	quality	level,	and	level	legend	is	present.	
Comment:	 	
	 	 Dimensions	for	judging	the	strength	of	a	recommendation	have	been	appropriately	considered,	
including	the	rationale	for	selection	and	any	citations,	if	applicable.	
Comment:	 	
	 	 Applicability	Issues	are	defined.	
Comment:	 	
	 	 Relevant	CCHMC	Tools	for	Implementation	are	defined,	if	any.	
Comment:	 	
	 	 Outcome	or	Process	Measures	are	defined.	
Comment:	 	
	 	 Systematic	search	strategy	is	defined.	
Comment:	 	
	 	 Relevant	CCHMC	Evidence-Based	Documents	are	listed.		If	no	documents,	then	”None	were	found.”	
Comment:	 	
	 	 Team	member(s),	including	credentials,	discipline	and/or	specialty	is	present.	
Comment:	 	
	 	 Known	Conflicts	of	Interest	are	declared	by	each	team	member.	
Comment:	 	
	 	 I,	the	reviewer,	was	not	involved	with	the	development	of	this	BESt.	
Comment:	 	
	
	
	
	
	
	 Meets	all	criteria	(may	be	posted)	
	 Does	not	meet	all	criteria	(return	to	EBDMinfo@cchmc.org	for	required	changes)	
	
	
BESt	is	attached	with	tracked	changes:	 	Yes		 	No,	not	attached	
	
	
Additional	Comments	/	Suggestions:	 	
	
	
	
	
	
	 	
Reviewers’	Names	 Date	Reviewed	
	
	
 
102 
Appendix S 
Final BESt  
  
 
 
Patient Services/NGT/OGT Placement/Confirmation/BESt 024 
 
Best Evidence Statement (BESt) 
 
 
Date: August 22, 2011 
 
Confirmation of Nasogastric/Orogastric Tube (NGT/OGT) Placement 
 
Clinical Question 
P (population/problem) Among pediatric patients who require NGT/OGT placement 
I (intervention) does auscultation, pH, enzyme, visual inspection of aspirate, and CO2 testing 
C (comparison) compared to radiological verification 
O (outcome) provide an accurate confirmation of tube placement? 
 
P (population/problem) Among pediatric patients who require NGT/OGT placement 
I (intervention) are tube length predictions using age-related height –based (ARHB) methods 
C (comparison) compared to nose-ear-xiphoid (NEX) morphological measurements 
O (outcome) more accurate in predicting tube length? 
 
Target Population Pediatric patients who require NGT/OGT placement for feeding or gastric 
decompression. 
 
Recommendations (See Table of Recommendation Strength following references) 
1.  It is recommended that radiologic verification be used to determine NGT/OGT placement in pediatric 
patients who are at high risk of aspiration or when non-radiologic methods are not feasible, or results are 
unclear. 
 
Note: Pediatric patients at risk for incorrect tube placement include those who have neurologic impairment 
and other conditions which may increase the difficulty of safe, effective tube placement and include patients 
who are obtunded, sedated, unconscious, critically ill and those with reduced gag reflex or static 
encephalopathy (Metheny, 1994a [3a], Phang, 2004 [3b], Ellett 1999 [4b]). 
 
Note: Radiologic verification is considered the gold standard but may contribute to higher costs, decreased 
convenience, and increased radiation exposure (Metheny 1994a [3a], Metheny2002 [3a], Nyqvist 2005 [4a], 
Peter 2008 [4a], Ellett 1999 [4b], Westhus 2004 [4b]). 
 
2.  It is  recommended that non-radiological verification methods be used to confirm placement of 
NGT/OGT in  pediatric patients who are not considered at high risk for aspiration as outlined above, 
using the following method: 
 
Aspirate pH testing: Use aspirate pH <5 to confirm gastric placement (Ellett, 2005 [3a], 
Metheny, 1999b [4a], Metheny, 2002 [3a], Metheny, 1999a [4a], Metheny, 1993 [3a],) (See 
Table 1). 
 
Note: Gastric aspirate pH mean is statistically lower (higher acidity) compared to intestinal aspirate mean pH 
(Metheny, 1999a [4a]). 
 
Note: Mean pH of respiratory aspirate from the tracheobroncheal tree or plural space is statistically higher 
than gastric aspirate pH (Metheny, 1999a [4a]). 
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Note: pH testing can be accurately done with pH paper or pH meter (Ellet, 2005 [3a], Metheny, 1994a [3a], 
Westhus, 2004[4b]). 
 
Note: Mean values for gastric aspirate are not significantly different when patients are fed or fasting 
(Metheny, 2002[3a], Metheny, 1999a [4a]). 
 
Note: Mean values for aspirate are not significantly different when patients are on or off acid suppression 
medications (Ellett, 2005[3a], Metheney, 1994a [3a]). 
 
Note:  Auscultation has been shown to have poor reliability and is not recommended as a sole verification 
method.  (Ellett, 1999[4b], Metheny, 2002 [3a], Metheny, 1990 [4a], Neumann, 1995 [3b]). 
 
Note: Visual inspection of aspirate has not been shown to be a reliable sole method of verification; however, 
it may have some use when done in conjunction with pH testing (Garpure, 2000[4a], Metheny, 2002 [3a], 
Metheny, 1999b [4a], Metheny, 1994a [3a], Metheny, 1994b [4a], Phang, 2004 [3b], Westhaus 2004 [4b]). 
 
Note: Aspirate testing of enzyme levels for bilirubin, pepsin, and trypsin also provide an alternate method of 
verification, but it is limited to laboratory assessment (Ellett 2005 [3a], Gharpure, 2000 [4a], Metheny, 2002 
[3a], Metheny, 1999 a [4a], Westhaus, 2004 [4b]). 
 
Note: While CO2 monitoring provides an alternate method of verification, it requires a capnograph monitor to 
determine incorrect tube placement (Ellett, 2005 [3a]). 
 
 
 
3.  It is recommended that NGT/OGT length be predicted as follows: 
 
For children >2 weeks, age- related height-based (ARHB) methods are more accurate than other 
morphological measures such as  nose-ear-xiphoid (NEX) or nose-ear-mid-xiphoid-umbilicus 
(NEMU) in predicting tube length  and can be calculated using prediction equation tables (see Table 
2) (Beckstrand, 2007 [4a], Ellett, 1992 [4b], Klausner, 2002 [2b], Putnam, 1991[4a], Strobel, 1979 
[4b]). 
 
For neonates less than 2 weeks of age, patients with short stature, or if unable to obtain an accurate 
height, use morphological measurements such as NEX or NEMU (Beckstrand, 2007 [4a]). 
 
Note: Measurement using the NEMU method for tube length prediction versus the NEX method is slightly 
more reliable for tube length prediction (Beckstrand, 2007[4a], Gallaher, 1993 [3a] Weibley, 1987[4a]). 
 
Note: Short stature is defined as a standing height more than 2 standard deviations (SDs) below the mean (or 
below the 2.5 percentile) for sex (Cohen, 2008, [5])]. 
 
Note: Mark tube length at the nare for NGT, or corner of the mouth for OGT with indelible permanent marker 
and document amount of tube remaining (external visible length) (EVL) outside the patient in the patient 
record (Weibley, 1987 [4a]). 
 
See Figure 1 for Algorithm: Confirmation of NGT/OGT Placement 
 
Grade for the Body of Evidence is moderate. 
 
Relevant CCHMC policies/procedures: 
I-229 Confirmation of Proper Position of NG/NJ Tubes 
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Mosby Skill: Nasogastric/Orogastric Tube: Insertion and Removal; Marking and Verification 
 
Discussion/summary of evidence 
Radiologic verification of NGT/OGT is considered the gold standard.  However, non-radiologic verification methods 
provide an accurate alternative in patients who are not considered at high risk for aspiration.  Bedside pH testing of 
gastric aspirate can be used to confirm placement (Ellett, 2005 [3a], Metheny, 1999b [4a], Metheny, 2002 [3a], 
Metheny, 1999a [4a], Metheny, 1993 [3a]).  Although widely used, the auscultatory method of tube verification has 
been shown to have poor reliability and is not recommended as a sole verification method (Ellett, 1999[4b], Metheny, 
2002 [3a], Metheny, 1990 [4a], Neumann, 1995 [3b]). In addition, visual inspection of aspirate has not been shown to 
be a reliable sole method of verification; however, it may have some use when done in conjunction with pH testing 
(Garpure, 2000[4a], Metheny, 2002 [3a], Metheny, 1999b [4a], Metheny, 1994a [3a], Metheny, 1994b [4a], Phang, 
2004 [3b], Westhaus 2004 [4b].  Aspirate testing of enzyme levels for bilirubin, pepsin, and trypsin also provide an 
alternate method of verification, but are limited to laboratory assessment (Ellett, 2005 [3a], Gharpure, 2000 [4a], 
Metheny , 2002 [3a], Metheny, 1999 a[4a], Westhaus, 2004 [4b]).  While CO2 monitoring provides an alternate 
method of verification, it requires a capnograph monitor to determine incorrect tube placement (Ellett, 2005 [3a]). 
There is moderate evidence that improving the accuracy of NGT/OGT length prior to insertion will enhance the 
precision of successful tube placement (Beckstrand, 2007 [4a], Ellett, 1992 [4b], Gallaher, (1993) [3a], Klausner, 
2002 [2b], Putnam, 1991 [4a], Strobel, 1979 [4b]). Magnet tracking systems have been shown to be accurate but the 
clinical feasibility of their use needs further investigation (Bercik, 2005). 
 
Health Benefits, Side Effects and Risks 
Non-radiological NGT/OGT placement methods contribute to decreased radiation exposure for pediatric 
patients (Metheny, 2002 [3a], Peter, 2008 [4a], Westhus, 2004 [4b], Nyqvist, 2005 [4a], Metheny, 1994a 
[3a], Ellett, 1999 [4b]). Side effects include improperly placed tube due to measurement or placement error. 
Risks of improperly placed tubes include aspiration, feeding into the wrong place, and irritation. 
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Note: Full tables of evidence grading system available in separate document: 
Table of Evidence Levels of Individual Studies by Domain, Study Design, & Quality (abbreviated table below) 
Grading a Body of Evidence to Answer a Clinical Question 
Judging the Strength of a Recommendation (abbreviated table below) 
 
Table of Evidence Levels (see note above) 
Quality level Definition 
1a† or 1b† Systematic review, meta-analysis, or meta- 
synthesis of multiple studies 
2a or 2b Best study design for domain 
3a or 3b Fair study design for domain 
4a or 4b Weak study design for domain 
5 Other: General review, expert opinion, case 
report, consensus report, or guideline 
†a = good quality study;  b = lesser quality study 
 
 
Table of Recommendation Strength (see note above) 
Strength Definition 
“Strongly recommended” There is consensus that benefits clearly outweigh risks and burdens 
(or visa-versa for negative recommendations). 
“Recommended” There is consensus that benefits are closely balanced with risks and burdens. 
No recommendation made There is lack of consensus to direct development of a recommendation. 
  
Dimensions: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process 
that incorporates critically appraised evidence, clinical experience, and other dimensions as listed below. 
1.  Grade of the Body of Evidence (see note above) 
2.  Safety / Harm 
3.  Health benefit to patient (direct benefit) 
4.  Burden to patient of adherence to recommendation (cost, hassle, discomfort, pain, motivation, ability to adhere, time) 
5.  Cost-effectiveness to healthcare system (balance of cost / savings of resources, staff time, and supplies based on published studies or 
onsite analysis) 
6.  Directness (the extent to which the body of evidence directly answers the clinical question [population/problem, intervention, 
comparison, outcome]) 
7.  Impact on morbidity/mortality or quality of life 
 
 
 
Supporting information 
 
Introductory/background information 
Error rates for placement of enteral tubes in any location, other than the intended location, can be up to 43.5% in 
pediatric settings (Ellett, 1999).  A small percentage of enteral tubes, reported as 1%-4% in adult intensive care 
settings but unknown in pediatrics, are incorrectly placed within the respiratory tract with potentially serious 
consequences (Ellett, 2005, Metheny, 1999b, Metheny, 1994a).  Children who are comatose, semi-comatose, or have 
swallowing problems have higher placement errors outside the intended location (Ellett, 1999) and ought to be 
considered at higher risk for incorrect placement.  Radiography is considered the gold standard for documenting tube 
placement (Ellett, 1999, Metheny, 2004).  However, routine radiologic tube verification in pediatric and adolescent 
patients increases the risk of excessive radiation exposure, increases patient and healthcare costs, and slows the 
delivery of clinical care (Ellett, 1999, Neumann, 1995).  Due to these patient and healthcare risks, the evidence for the 
best methods to accurately verify NG/OG placement was reviewed. 
 
Group/team members 
Revision Group/Team Leader: Sherri Sievers, MSN, RN, CNP, Department of Anesthesia 
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Support personnel: Barbara K. Giambra, MS, RN, CPNP, Center for Professional Excellence, 
Research and Evidence-Based Practice 
Ad hoc team members: 
Development Group 
Kim Klotz, BSN, RN, Vascular Access Team, Chair 
Lois Siegle, BSN, RN, Home Care Services 
Anne Longo, MBA, BSN, RN-BC, Center for Professional Excellence, Education 
Karen Burkett, MS, CNP, RN, Center for Professional Excellence, Research & Evidence-Based 
Practice 
 
Search strategy 
OVID Databases 
Medline, CINAHL, PubMed and the Cochrane Database for Systematic Reviews (CDSR) 
OVID Filters 
Publication Date: 1996 to present 
Limits: Humans and English Language 
Study Type: Highest quality evidence 
Search Terms and MeSH Terms 
Children, nasogastric tube, NG tube, aspirate, auscultation, radiology, morphological, age-related height 
based, accuracy, prediction, length. 
Additional articles identified from reference lists and clinicians 
 
Applicability issues 
 
Can be applied to pediatric and adolescent patients in a hospital setting. 
Methods which can be performed at the bedside allow greater convenience for the patients, families and 
staff, and may contribute to decreased costs. 
Required equipment is minimal and includes pH strips which are sensitive enough to make a determination 
of < 5. A pH meter was not found to be more accurate than pH strips for measuring gastric pH. (Westhaus, 
2004) [4b]. 
 
Copies of this Best Evidence Statement (BESt) are available online and may be distributed by any organization for the global purpose of 
improving child health outcomes.  Website address: http://www.cincinnatichildrens.org/svc/alpha/h/health-policy/ev-based/default.htm 
Examples of approved uses of the BESt include the following: 
•  copies may be provided to anyone involved in the organization’s process for developing and implementing evidence based care; 
•  hyperlinks to the CCHMC website may be  placed on the organization’s website; 
•  the BESt may be adopted or adapted for use within the organization, provided that CCHMC receives appropriate attribution on all written or 
electronic documents; and 
•  copies may be provided to patients and the clinicians who manage their care. 
 
Notification of CCHMC at  HPCEInfo@cchmc.org for any BESt adopted, adapted, implemented or hyperlinked by the organization is 
appreciated. 
 
For more information about CCHMC Best Evidence Statements and the development process, contact Center for Professional 
 
Excellence/Research and Evidence-based Practice office at CPE-EBP-Group@cchmc.org . 
 
 
Note 
This Best Evidence Statement addresses only key points of care for the target population; it is not intended to be a comprehensive 
practice guideline.  These recommendations result from review of literature and practices current at the time of their formul ation.  This 
Best Evidence Statement does not preclude using care modalities proven efficacious in studies published subsequent to the current 
revision of this document.  This document is not intended to impose standards of care preventing selective variances from the 
recommendations to meet the specific and unique requirements of individual patients.  Adherence to this Statement is voluntary.  The 
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clinician in light of the individual circumstances presented by the patient must make the ultimate judgment regarding the pri ority of 
any specific procedure. 
 
Reviewed against quality criteria by two independent reviewers 
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Table 1: Summary of findings for Gastric, Intestinal and Respiratory pH 
 
Study Sample Gastric Aspirate pH 
mean (SD) 
Intestinal Aspirate 
pH mean (SD) 
Respiratory 
Aspirate pH mean 
(SD) 
Ellett, 2005[3a] 3days -7 years 
n=72 
4.5 (1.4) No data No data 
Metheny, 
1999b[4a] 
Neonates 
n=90 
4.32 (0.20) 7.80 No data 
Metheny, 
2002[3a] 
18 years-87 years 
n=80 
5.7 (0.1) * 6.6 (0.1)* No data 
Metheny , 
1999a[4a] 
14yrs-adult 
n=587 
3.90 (0.15) 7.35 (0.06) 7.73 (0.04) 
(tracheobronchial 
tree) 
Metheny, 
1993[3a] 
18yrs-94 yrs 
n=794 
3.52 (2.02) 7.05 (1.26) No data 
Phang, 2004[3b] 25yrs-92yrs 
n=181 
4.8 (2.3) 
Acid supp 
5.0 (2.3) 
No acid 
4.0 (2.5) 
7.1 (1.0) 
Acid supp 
7.2+-1.0 
No acid 
6.7+-1.1 
No data 
Metheny, 
1994a[3a] 
 
n=800 
3.52 (2.02) 
Acid 
3.84 (2.06) 
No acid 
3.12 (1.90) 
7.05 (1.26) 7.38 (0.59) (plural 
space) 
Westhus,2004[4b] Birth-14yrs 
n=56 
4.1 (0.32) 7.5 (0.33) No data 
Garpure, 
2000[4a] 
8 days -19yrs 
n=96 
4.1 
Fed 5.0 
Not fed 4.0 
6.8 
Fed 6.6 
Not fed7.0 
No data 
*standard error of the mean rather than SD 
 
Table 2:  Age-related height-based (ARHB) prediction equations for the internal distance to the body of the 
stomach for use in clinical practice, by route of insertion and age in children. 
 
 
Route Age Group (months) Predicted internal distance to the body of the stomach 
 
 
Oral 
 
Age < 28 
28 < age < 100 
100 < age < 121 
Age > 121 
 
9.1cm + 0.183 (height cm) + 6 cm + 1.5 cm = 16.6 + 0.183 (height cm) 
9.1cm + 0.183 (height cm) + 8 cm + 3 cm = 20.1 + 0.183 (height cm) 
4.5cm + 0.218 (height cm) + 7.5 cm + 5 cm = 17 + 0.218 (height cm) 
4.5cm + 0.218 (height cm) + 9 cm + 5 cm = 18.5 + 0.218 (height cm) 
 
Nasal 
 
Age < 28 
28 < age < 100 
100 < age < 121 
Age > 121 
 
10.1cm + 0.197 (height cm) + 6 cm + 1.5 cm = 17.6 + 0.197 (height cm) 
10.1cm + 0.197 (height cm) + 8 cm + 3 cm = 21.1 + 0.197 (height cm) 
4.5cm + (2.7) + 0.218 (height cm) + 6.5 cm + 5 cm = 18.7 + 0.218 (height cm) 
4.5cm + (2.7) + 0.218 (height cm) + 9 cm + 5 cm = 21.2 + 0.218 (height cm) 
Note: the distance measured is to the bottom of the distal pore on the tube 
Beckstrand, (2007) [4a] Used with permission 
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Appendix U 
 Inclusion Criteria 
 
 
Inclusion Criteria
Note: NGC is currently re -evaluating the definition and inclusion criteria described below. This work will be informed by a number of efforts, such as review 
of the literature, guidance from the NGC/NQMC Editorial Board, previous and ongoing studies of the Institute of Medicine, and your input. We invite you to 
send your comments on this matter to info@guideline.gov .
Definition of Clinical Practice Guideline
NGC employs the definition of clinical practice guideline developed by the Institute of Medicine (IOM). 
Clinical practice guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific
clinical circumstances. [Institute of Medicine. (1990). Clinical Practice Guidelines: Directions for a New Program, M.J. Field and K.N. Lohr (eds.) 
Washington, DC: National Academy Press. page 38].
Criteria for Inclusion of Clinical Practice Guidelines in NGC
All of the criteria below must be met for a clinical practice guideline to be included in NGC.
1. The clinical practice guideline contains systematically developed statements that include recommendations, strategies, or information that assists 
physicians and/or other health care practitioners and patients to make decisions about appropriate health care for specific clinical circumstances.  
2. The clinical practice guideline was produced under the auspices of medical specialty associations; relevant professional societies, public or private 
organizations, government agencies at the Federal, State, or local level; or health care organizations or plans. A clinical practice guideline developed 
and issued by an individual not officially sponsored or supported by one of the above types of organizations does not meet the inclusion criteria for 
NGC. 
3. Corroborating documentation can be produced and verified that a systematic literature search and review of existing scientific evidence published in 
peer reviewed journals was performed during the guideline development. A guideline is not excluded from NGC if corroborating documentation can be 
produced and verified detailing specific gaps in scientific evidence for some of the guideline's recommendations. 
4. The full text guideline is available upon request in print or electronic format (for free or for a fee), in the English language. The guideline is current and 
the most recent version produced. Documented evidence can be produced or verified that the guideline was developed, reviewed, or revised within the
last five years. 
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Template of Guideline Attributes
The Template of Guideline Attributes is the primary tool used to develop NGC guideline summaries. This template lists each guideline attribute, its 
description, and controlled vocabulary values where applicable.
Indexing Attribute
Guideline Summaries are also indexed for the following attributes to support Advanced Searches  and By Topic  browse of the database. 
Guideline Title Identifies the complete title of the guideline.
Bibliographic Source(s) Identifies the complete bibliographic source(s) for the published guideline as disseminated by the guideline 
developer(s). The number of references cited is included for each source. Links are provided to PubMed 
where applicable.
Guideline Status Identifies whether the guideline is a revised or updated version of a previously issued document as well as 
whether an update is currently in progress.
Regulatory Alert
FDA Warning/Regulatory Alert Identifies important warnings and/or revised regulatory information released by the U.S. Food and Drug 
Administration (FDA) or other official regulatory body for a drug and/or device for which recommendations 
are provided in the original guideline document.
Scope
Disease/Condition(s) Identifies the major areas of clinical medicine or health care addressed in the guideline. Values are 
expressed using the natural language expressions found in the text of the guideline.
Guideline Category Classifies the major focus of the guideline. Values are selected from the appropriate concepts in the 
Classification Scheme .
Clinical Specialty Classifies the clinical specialties that might use the guideline professionally. Values are selected from the 
appropriate concepts in the Classification Scheme .
Intended Users Classifies the groups intended to use the guideline. Values are selected from the appropriate concepts in 
the Classification Scheme .
Guideline Objective(s) Describes the objectives of the guideline, as specified in the guideline text by the developers.
Target Population Describes the target population(s) addressed in the guideline.
Identifies restrictions on guideline use such as within a managed care plan or geographic region.
Interventions and Practices Considered Identifies the specific clinical interventions and practices considered in the guideline. Values are 
expressed using natural language expressions found in the text of the guideline.
Major Outcomes Considered Describes the most important specific outcomes or performance measures considered in the guideline. 
Includes patient outcomes described in treatment guidelines and diagnostic test performance 
characteristics described in diagnosis or screening guidelines.
Methodology
Methods Used to Collect/Select the 
Evidence
Classifies the methods used to collect and select the evidence that was evaluated. Values are chosen 
from the appropriate concepts in the Classification Scheme .
Description of Methods Used to 
Collect/Select the Evidence
Describes/summarizes the specific methods used to collect and select the evidence, as identified in the 
text of the guideline or by the guideline developer. Can include detailed search strategies, lists of journals 
scanned, keywords, database sources, inclusion and exclusion criteria, etc.
Number of Source Documents Identifies the number of source documents that were identified by the methods described above under 
"Description of Methods used to Collect/Select the Evidence."
The number of source documents is NOT the number of references.
Methods Used to Assess the Quality and 
Strength of the Evidence
Classifies the methods used by the guideline developer to determine what relative importance to give the 
evidence they obtained. Values are selected from the appropriate concepts in the Classification Scheme .
Rating Scheme for the Strength of the 
Evidence
Presents rating scheme for strength of evidence, when given.
Methods Used to Analyze the Evidence Classifies the methods used by the guideline developer to evaluate the data in the evidence they 
obtained. Values are chosen from the appropriate concepts in the Classification Scheme .
Description of Methods Used to Analyze 
the Evidence
Describes the methods used to analyze the evidence. Presents additional definition for the values 
presented under "Methods to Analyze the Evidence" (for example, defines "systematic" or summarizes the 
details of the meta -analyses).
Methods Used to Formulate the 
Recommendations
Identifies the methods used to translate evidence into statements that will assist practitioners and 
patients make decisions about appropriate health care for specific clinical circumstances. Values are 
chosen from the appropriate concepts in the Classification Scheme .
Description of the Methods used to 
Formulate the Recommendations
Captures the details of the methods used to translate evidence into recommendation statements, if so 
provided in the guideline documents. Issues, such as cost, patient preference, and values, considered by 
the guideline developers during recommendation formulation are also captured.
Rating Scheme for the Strength of the 
Recommendations
Captures the weighted scheme used by the guideline developer to determine what relative strength or 
importance to give to the recommendations being made. The relative strength or importance may be 
derived from the quality and strength of the evidence upon which recommendations are based, from a 
strictly clinical perspective, or both.
Cost Analysis Describes any formal cost analysis performed and any published cost analyses reviewed.
Method of Guideline Validation Lists the method(s) used to validate the recommendations of the guideline. Validation is defined as "the 
results of any external review, comparison with guidelines from other groups or clinical testing of guideline 
use" (Hayward RSA, et al. More informative abstracts of articles describing clinical practice guidelines, 
Ann Intern Med 1993;118:731 -737). 
Values are chosen from the appropriate concepts in the Classification Scheme .
Description of Method of Guideline 
Validation
Captures the details of the method(s) used by the guideline developer to validate the guideline, if so 
provided in the guideline document.
Recommendations
Major Recommendations Identifies the major recommendations, copied verbatim from the guideline, or supplied separately by the 
guideline developer.
Clinical Algorithm(s) Identifies which of the recommendations are expressed in the form of clinical algorithm(s) and where the 
algorithm(s) are provided.
Evidence Supporting the Recommendations
References Supporting the 
Recommendations
Lists the references of evidence supporting the recommendations when explicit recommendations are 
offered and when the references are supplied with those explicit recommendations. This field opens in a 
new window. Links are provided to PubMed where applicable.
Type of Evidence Supporting the 
Recommendations
Describes the type of evidence supporting the recommendations.
Benefits/Harms of Implementing the Recommendations
Potential Benefits Describes the anticipated benefits associated with implementing the guideline's recommendations, as 
stated in the guideline text, to target populations or intended users. Where applicable, the field also 
includes information on the major subgroup(s) of patients within the target population most likely to 
benefit from the guideline recommendations, as identified by the guideline developer.
Potential Harms Description of the anticipated harms, potential risks or adverse consequences associated with the 
guideline's recommendations, as stated in the guideline text, to target populations or intended users. 
Where identified by the original guideline document, the major subgroup(s) of patients within the target 
population most likely to suffer harm/adverse consequences associated with the guideline 
recommendations will also be described.
Contraindications
Contraindications Identifies the instances (e.g., co -morbidities), as provided by the guideline developers, which might 
render the use of medications or procedures improper, undesirable, or inadvisable.
Qualifying Statements
Qualifying Statements Presents qualifying statements or important caveats pertaining to the major recommendations of the 
guideline emphasized by the guideline developer. Identifies the area of uncertainty and presents a brief 
description of how the guideline developer addressed this uncertainty in developing the major 
recommendations of the guideline.
Only caveats pertaining to the major recommendations are included. This attribute may also present 
information regarding uncertainty or controversies in the field identified by the guideline developer that 
prevents formulation of specific recommendations regarding important aspects within the guideline.
Disclaimer-type statements are also captured in this field.
Implementation of the Guideline
Description of Implementation Strategy Describes specific strategies, aims, performance measures, or plans for implementing the guideline 
recommendations, if presented in the guideline or supplied by the guideline developer.
Implementation Tools Classifies the types of implementation tools provided by the guideline developer to facilitate the 
implementation of their guideline. Values are selected from the appropriate concepts in the Classification 
Scheme
Related NQMC Measures Identifies link(s) to related quality measures or measure sets in the National Quality Measures 
Institute of Medicine (IOM) National Healthcare Quality Report Categories
IOM Care Need Classifies the guideline into one of four Institute of Medicine (IOM) care need classifications: End of life 
care; Getting better; Living with illness; Staying healthy.
IOM Domain Classifies the guideline into one or more of the four Institute of Medicine (IOM) care domains: 
Effectiveness; Patient -centeredness; Safety; Timeliness.
Identifying Information and Availability
Bibliographic Source(s) Identifies the complete bibliographic source(s) for the published guideline as disseminated by the guideline 
developer(s). The number of references cited is included for each source. Links are provided to PubMed 
where applicable.
Adaptation Identifies that the guideline has been adapted from another guideline and identifies the source 
document.
Date Released Identifies the date the guideline was released to the public.
Guideline Developer(s) Identifies the organization(s) responsible for the development of the guideline. Each organization is 
classified by the major designation or function (derived from the Organization Type attribute), such as 
"Medical Specialty Society" or "Professional Association."
Guideline Developer Comment If the guideline developer is a consortium or represents a group of organizations, this attribute identifies 
the individual organizations by name.
Source(s) of Funding Identifies source(s) of financial support for guideline development, as identified in the guideline text or by 
the guideline developer. Lists any grant numbers associated with funding, as identified in the guideline 
text or by the guideline developer.
Guideline Committee Identifies formal name, if any, of committee/subcommittee within the guideline developer organization(s) 
responsible for developing the guideline.
Composition of Group That Authored the 
Guideline
Describes the composition of the group/committee that authored the guideline, including professional 
degrees and affiliations, and lists the names of individual committee members, where given.
Financial Disclosures/Conflicts of Interest Captures relationships between individuals of the guideline development committee/group and for -profit 
and not-for-profit companies or organizations that could potentially influence that individual's contribution 
to the guideline's development.
Endorser(s) Identifies organization(s) that have endorsed the guideline, as identified in the text of the guideline 
document or explicitly by the guideline developer. Each organization is classified by the major designation 
or function (derived from the Organization Type attribute), such as "Medical Specialty Society" or 
"Professional Association."
Guideline Status Identifies whether the guideline is a revised or updated version of a previously issued document as well as 
whether an update is currently in progress.
Guideline Availability Identifies information about the availability of the guideline. Provides, where possible, information 
regarding electronic (including hypertext links to the full -text) copies and ordering information for print 
copies.
Availability of Companion Documents Identifies the companion documents produced by the guideline developer that are considered relevant to 
the guideline. These companion documents are not necessarily available within NGC. 
For example, Quick Reference Guides and Technical Reports , all of which would be listed here, accompany 
guidelines produced by the Agency for Healthcare Research and Quality (AHRQ) (formerly the Agency for 
Health Care Policy and Research [AHCPR]).
Patient Resources Identifies patient resources that are directly related (i.e., derived and/or prepared from the guideline by 
the guideline developer) to the guideline included in NGC. The patient information is not reviewed by NGC 
to establish whether or not it accurately reflects the original guideline's content.
NGC Status Identifies when the guideline was completed or revised by ECRI Institute, and verified by the submitting 
organization(s).
Copyright Statement Provides the copyright statement of the organization that submitted the guideline.
Disclaimer
Disclaimer Provides disclaimer information about the relationship between NGC (including its sponsor, the Agency for 
Healthcare Research and Quality (AHRQ), and its contractor, ECRI Institute) and the guidelines and 
guideline developers represented on the Web site. 
Age of the Target 
Population
Describes the age group(s) represented by the target population, enabling users to restrict their searches to a particular age 
group(s).
Sex of the Target 
Population
Classifies the sex(es) represented by the target population, enabling users to restrict their searches to a particular gender.
Disease/Condition(s) NGC uses Medical Subject Headings (MeSH) produced by the U.S. National Library of Medicine (NLM)  , along with other 
controlled vocabularies, such as the International Classification of Diseases (ICD), incorporated into NLM's Unified Medical 
Language System (UMLS)   to classify disease concepts related to NGC guidelines.
Treatment/Intervention NGC uses Medical Subject Headings (MeSH) produced by the U.S. National Library of Medicine (NLM)  , along with other 
controlled vocabularies, such as the U.S. Health Care Financing Administration (HCFA) Common Procedure Coding System and ECRI
Institute's Universal Medical Device Nomenclature System (UMDNS), incorporated into NLM's Unified Medical Language System 
(UMLS)  to classify treatment/intervention concepts related to NGC guidelines.
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Template of Guideline Attributes
The Template of Guideline Attributes is the primary tool used to develop NGC guideline summaries. This template lists each guideline attribute, its 
description, and controlled vocabulary values where applicable.
Indexing Attribute
Guideline Summaries are also indexed for the following attributes to support Advanced Searches  and By Topic  browse of the database. 
Guideline Title Identifies the complete title of the guideline.
Bibliographic Source(s) Identifies the complete bibliographic source(s) for the published guideline as disseminated by the guideline 
developer(s). The number of references cited is included for each source. Links are provided to PubMed 
where applicable.
Guideline Status Identifies whether the guideline is a revised or updated version of a previously issued document as well as 
whether an update is currently in progress.
Regulatory Alert
FDA Warning/Regulatory Alert Identifies important warnings and/or revised regulatory information released by the U.S. Food and Drug 
Administration (FDA) or other official regulatory body for a drug and/or device for which recommendations 
are provided in the original guideline document.
Scope
Disease/Condition(s) Identifies the major areas of clinical medicine or health care addressed in the guideline. Values are 
expressed using the natural language expressions found in the text of the guideline.
Guideline Category Classifies the major focus of the guideline. Values are selected from the appropriate concepts in the 
Classification Scheme .
Clinical Specialty Classifies the clinical specialties that might use the guideline professionally. Values are selected from the 
appropriate concepts in the Classification Scheme .
Intended Users Classifies the groups intended to use the guideline. Values are selected from the appropriate concepts in 
the Classification Scheme .
Guideline Objective(s) Describes the objectives of the guideline, as specified in the guideline text by the developers.
Target Population Describes the target population(s) addressed in the guideline.
Identifies restrictions on guideline use such as within a managed care plan or geographic region.
Interventions and Practices Considered Identifies the specific clinical interventions and practices considered in the guideline. Values are 
expressed using natural language expressions found in the text of the guideline.
Major Outcomes Considered Describes the most important specific outcomes or performance measures considered in the guideline. 
Includes patient outcomes described in treatment guidelines and diagnostic test performance 
characteristics described in diagnosis or screening guidelines.
Methodology
Methods Used to Collect/Select the 
Evidence
Classifies the methods used to collect and select the evidence that was evaluated. Values are chosen 
from the appropriate concepts in the Classification Scheme .
Description of Methods Used to 
Collect/Select the Evidence
Describes/summarizes the specific methods used to collect and select the evidence, as identified in the 
text of the guideline or by the guideline developer. Can include detailed search strategies, lists of journals 
scanned, keywords, database sources, inclusion and exclusion criteria, etc.
Number of Source Documents Identifies the number of source documents that were identified by the methods described above under 
"Description of Methods used to Collect/Select the Evidence."
The number of source documents is NOT the number of references.
Methods Used to Assess the Quality and 
Strength of the Evidence
Classifies the methods used by the guideline developer to determine what relative importance to give the 
evidence they obtained. Values are selected from the appropriate concepts in the Classification Scheme .
Rating Scheme for the Strength of the 
Evidence
Presents rating scheme for strength of evidence, when given.
Methods Used to Analyze the Evidence Classifies the methods used by the guideline developer to evaluate the data in the evidence they 
obtained. Values are chosen from the appropriate concepts in the Classification Scheme .
Description of Methods Used to Analyze 
the Evidence
Describes the methods used to analyze the evidence. Presents additional definition for the values 
presented under "Methods to Analyze the Evidence" (for example, defines "systematic" or summarizes the 
details of the meta -analyses).
Methods Used to Formulate the 
Recommendations
Identifies the methods used to translate evidence into statements that will assist practitioners and 
patients make decisions about appropriate health care for specific clinical circumstances. Values are 
chosen from the appropriate concepts in the Classification Scheme .
Description of the Methods used to 
Formulate the Recommendations
Captures the details of the methods used to translate evidence into recommendation statements, if so 
provided in the guideline documents. Issues, such as cost, patient preference, and values, considered by 
the guideline developers during recommendation formulation are also captured.
Rating Scheme for the Strength of the 
Recommendations
Captures the weighted scheme used by the guideline developer to determine what relative strength or 
importance to give to the recommendations being made. The relative strength or importance may be 
derived from the quality and strength of the evidence upon which recommendations are based, from a 
strictly clinical perspective, or both.
Cost Analysis Describes any formal cost analysis performed and any published cost analyses reviewed.
Method of Guideline Validation Lists the method(s) used to validate the recommendations of the guideline. Validation is defined as "the 
results of any external review, comparison with guidelines from other groups or clinical testing of guideline 
use" (Hayward RSA, et al. More informative abstracts of articles describing clinical practice guidelines, 
Ann Intern Med 1993;118:731 -737). 
Values are chosen from the appropriate concepts in the Classification Scheme .
Description of Method of Guideline 
Validation
Captures the details of the method(s) used by the guideline developer to validate the guideline, if so 
provided in the guideline document.
Recommendations
Major Recommendations Identifies the major recommendations, copied verbatim from the guideline, or supplied separately by the 
guideline developer.
Clinical Algorithm(s) Identifies which of the recommendations are expressed in the form of clinical algorithm(s) and where the 
algorithm(s) are provided.
Evidence Supporting the Recommendations
References Supporting the 
Recommendations
Lists the references of evidence supporting the recommendations when explicit recommendations are 
offered and when the references are supplied with those explicit recommendations. This field opens in a 
new window. Links are provided to PubMed where applicable.
Type of Evidence Supporting the 
Recommendations
Describes the type of evidence supporting the recommendations.
Benefits/Harms of Implementing the Recommendations
Potential Benefits Describes the anticipated benefits associated with implementing the guideline's recommendations, as 
stated in the guideline text, to target populations or intended users. Where applicable, the field also 
includes information on the major subgroup(s) of patients within the target population most likely to 
benefit from the guideline recommendations, as identified by the guideline developer.
Potential Harms Description of the anticipated harms, potential risks or adverse consequences associated with the 
guideline's recommendations, as stated in the guideline text, to target populations or intended users. 
Where identified by the original guideline document, the major subgroup(s) of patients within the target 
population most likely to suffer harm/adverse consequences associated with the guideline 
recommendations will also be described.
Contraindications
Contraindications Identifies the instances (e.g., co -morbidities), as provided by the guideline developers, which might 
render the use of medications or procedures improper, undesirable, or inadvisable.
Qualifying Statements
Qualifying Statements Presents qualifying statements or important caveats pertaining to the major recommendations of the 
guideline emphasized by the guideline developer. Identifies the area of uncertainty and presents a brief 
description of how the guideline developer addressed this uncertainty in developing the major 
recommendations of the guideline.
Only caveats pertaining to the major recommendations are included. This attribute may also present 
information regarding uncertainty or controversies in the field identified by the guideline developer that 
prevents formulation of specific recommendations regarding important aspects within the guideline.
Disclaimer-type statements are also captured in this field.
Implementation of the Guideline
Description of Implementation Strategy Describes specific strategies, aims, performance measures, or plans for implementing the guideline 
recommendations, if presented in the guideline or supplied by the guideline developer.
Implementation Tools Classifies the types of implementation tools provided by the guideline developer to facilitate the 
implementation of their guideline. Values are selected from the appropriate concepts in the Classification 
Scheme
Related NQMC Measures Identifies link(s) to related quality measures or measure sets in the National Quality Measures 
Institute of Medicine (IOM) National Healthcare Quality Report Categories
IOM Care Need Classifies the guideline into one of four Institute of Medicine (IOM) care need classifications: End of life 
care; Getting better; Living with illness; Staying healthy.
IOM Domain Classifies the guideline into one or more of the four Institute of Medicine (IOM) care domains: 
Effectiveness; Patient -centeredness; Safety; Timeliness.
Identifying Information and Availability
Bibliographic Source(s) Identifies the complete bibliographic source(s) for the published guideline as disseminated by the guideline 
developer(s). The number of references cited is included for each source. Links are provided to PubMed 
where applicable.
Adaptation Identifies that the guideline has been adapted from another guideline and identifies the source 
document.
Date Released Identifies the date the guideline was released to the public.
Guideline Developer(s) Identifies the organization(s) responsible for the development of the guideline. Each organization is 
classified by the major designation or function (derived from the Organization Type attribute), such as 
"Medical Specialty Society" or "Professional Association."
Guideline Developer Comment If the guideline developer is a consortium or represents a group of organizations, this attribute identifies 
the individual organizations by name.
Source(s) of Funding Identifies source(s) of financial support for guideline development, as identified in the guideline text or by 
the guideline developer. Lists any grant numbers associated with funding, as identified in the guideline 
text or by the guideline developer.
Guideline Committee Identifies formal name, if any, of committee/subcommittee within the guideline developer organization(s) 
responsible for developing the guideline.
Composition of Group That Authored the 
Guideline
Describes the composition of the group/committee that authored the guideline, including professional 
degrees and affiliations, and lists the names of individual committee members, where given.
Financial Disclosures/Conflicts of Interest Captures relationships between individuals of the guideline development committee/group and for -profit 
and not-for-profit companies or organizations that could potentially influence that individual's contribution 
to the guideline's development.
Endorser(s) Identifies organization(s) that have endorsed the guideline, as identified in the text of the guideline 
document or explicitly by the guideline developer. Each organization is classified by the major designation 
or function (derived from the Organization Type attribute), such as "Medical Specialty Society" or 
"Professional Association."
Guideline Status Identifies whether the guideline is a revised or updated version of a previously issued document as well as 
whether an update is currently in progress.
Guideline Availability Identifies information about the availability of the guideline. Provides, where possible, information 
regarding electronic (including hypertext links to the full -text) copies and ordering information for print 
copies.
Availability of Companion Documents Identifies the companion documents produced by the guideline developer that are considered relevant to 
the guideline. These companion documents are not necessarily available within NGC. 
For example, Quick Reference Guides and Technical Reports , all of which would be listed here, accompany 
guidelines produced by the Agency for Healthcare Research and Quality (AHRQ) (formerly the Agency for 
Health Care Policy and Research [AHCPR]).
Patient Resources Identifies patient resources that are directly related (i.e., derived and/or prepared from the guideline by 
the guideline developer) to the guideline included in NGC. The patient information is not reviewed by NGC 
to establish whether or not it accurately reflects the original guideline's content.
NGC Status Identifies when the guideline was completed or revised by ECRI Institute, and verified by the submitting 
organization(s).
Copyright Statement Provides the copyright statement of the organization that submitted the guideline.
Disclaimer
Disclaimer Provides disclaimer information about the relationship between NGC (including its sponsor, the Agency for 
Healthcare Research and Quality (AHRQ), and its contractor, ECRI Institute) and the guidelines and 
guideline developers represented on the Web site. 
Age of the Target 
Population
Describes the age group(s) represented by the target population, enabling users to restrict their searches to a particular age 
group(s).
Sex of the Target 
Population
Classifies the sex(es) represented by the target population, enabling users to restrict their searches to a particular gender.
Disease/Condition(s) NGC uses Medical Subject Headings (MeSH) produced by the U.S. National Library of Medicine (NLM)  , along with other 
controlled vocabularies, such as the International Classification of Diseases (ICD), incorporated into NLM's Unified Medical 
Language System (UMLS)   to classify disease concepts related to NGC guidelines.
Treatment/Intervention NGC uses Medical Subject Headings (MeSH) produced by the U.S. National Library of Medicine (NLM)  , along with other 
controlled vocabularies, such as the U.S. Health Care Financing Administration (HCFA) Common Procedure Coding System and ECRI
Institute's Universal Medical Device Nomenclature System (UMDNS), incorporated into NLM's Unified Medical Language System 
(UMLS)  to classify treatment/intervention concepts related to NGC guidelines.
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Template of Guideline Attributes
The Template of Guideline Attributes is the primary tool used to develop NGC guideline summaries. This template lists each guideline attribute, its 
description, and controlled vocabulary values where applicable.
Indexing Attribute
Guideline Summaries are also indexed for the following attributes to support Advanced Searches  and By Topic  browse of the database. 
Guideline Title Identifies the complete title of the guideline.
Bibliographic Source(s) Identifies the complete bibliographic source(s) for the published guideline as disseminated by the guideline 
developer(s). The number of references cited is included for each source. Links are provided to PubMed 
where applicable.
Guideline Status Identifies whether the guideline is a revised or updated version of a previously issued document as well as 
whether an update is currently in progress.
Regulatory Alert
FDA Warning/Regulatory Alert Identifies important warnings and/or revised regulatory information released by the U.S. Food and Drug 
Administration (FDA) or other official regulatory body for a drug and/or device for which recommendations 
are provided in the original guideline document.
Scope
Disease/Condition(s) Identifies the major areas of clinical medicine or health care addressed in the guideline. Values are 
expressed using the natural language expressions found in the text of the guideline.
Guideline Category Classifies the major focus of the guideline. Values are selected from the appropriate concepts in the 
Classification Scheme .
Clinical Specialty Classifies the clinical specialties that might use the guideline professionally. Values are selected from the 
appropriate concepts in the Classification Scheme .
Intended Users Classifies the groups intended to use the guideline. Values are selected from the appropriate concepts in 
the Classification Scheme .
Guideline Objective(s) Describes the objectives of the guideline, as specified in the guideline text by the developers.
Target Population Describes the target population(s) addressed in the guideline.
Identifies restrictions on guideline use such as within a managed care plan or geographic region.
Interventions and Practices Considered Identifies the specific clinical interventions and practices considered in the guideline. Values are 
expressed using natural language expressions found in the text of the guideline.
Major Outcomes Considered Describes the most important specific outcomes or performance measures considered in the guideline. 
Includes patient outcomes described in treatment guidelines and diagnostic test performance 
characteristics described in diagnosis or screening guidelines.
Methodology
Methods Used to Collect/Select the 
Evidence
Classifies the methods used to collect and select the evidence that was evaluated. Values are chosen 
from the appropriate concepts in the Classification Scheme .
Description of Methods Used to 
Collect/Select the Evidence
Describes/summarizes the specific methods used to collect and select the evidence, as identified in the 
text of the guideline or by the guideline developer. Can include detailed search strategies, lists of journals 
scanned, keywords, database sources, inclusion and exclusion criteria, etc.
Number of Source Documents Identifies the number of source documents that were identified by the methods described above under 
"Description of Methods used to Collect/Select the Evidence."
The number of source documents is NOT the number of references.
Methods Used to Assess the Quality and 
Strength of the Evidence
Classifies the methods used by the guideline developer to determine what relative importance to give the 
evidence they obtained. Values are selected from the appropriate concepts in the Classification Scheme .
Rating Scheme for the Strength of the 
Evidence
Presents rating scheme for strength of evidence, when given.
Methods Used to Analyze the Evidence Classifies the methods used by the guideline developer to evaluate the data in the evidence they 
obtained. Values are chosen from the appropriate concepts in the Classification Scheme .
Description of Methods Used to Analyze 
the Evidence
Describes the methods used to analyze the evidence. Presents additional definition for the values 
presented under "Methods to Analyze the Evidence" (for example, defines "systematic" or summarizes the 
details of the meta -analyses).
Methods Used to Formulate the 
Recommendations
Identifies the methods used to translate evidence into statements that will assist practitioners and 
patients make decisions about appropriate health care for specific clinical circumstances. Values are 
chosen from the appropriate concepts in the Classification Scheme .
Description of the Methods used to 
Formulate the Recommendations
Captures the details of the methods used to translate evidence into recommendation statements, if so 
provided in the guideline documents. Issues, such as cost, patient preference, and values, considered by 
the guideline developers during recommendation formulation are also captured.
Rating Scheme for the Strength of the 
Recommendations
Captures the weighted scheme used by the guideline developer to determine what relative strength or 
importance to give to the recommendations being made. The relative strength or importance may be 
derived from the quality and strength of the evidence upon which recommendations are based, from a 
strictly clinical perspective, or both.
Cost Analysis Describes any formal cost analysis performed and any published cost analyses reviewed.
Method of Guideline Validation Lists the method(s) used to validate the recommendations of the guideline. Validation is defined as "the 
results of any external review, comparison with guidelines from other groups or clinical testing of guideline 
use" (Hayward RSA, et al. More informative abstracts of articles describing clinical practice guidelines, 
Ann Intern Med 1993;118:731 -737). 
Values are chosen from the appropriate concepts in the Classification Scheme .
Description of Method of Guideline 
Validation
Captures the details of the method(s) used by the guideline developer to validate the guideline, if so 
provided in the guideline document.
Recommendations
Major Recommendations Identifies the major recommendations, copied verbatim from the guideline, or supplied separately by the 
guideline developer.
Clinical Algorithm(s) Identifies which of the recommendations are expressed in the form of clinical algorithm(s) and where the 
algorithm(s) are provided.
Evidence Supporting the Recommendations
References Supporting the 
Recommendations
Lists the references of evidence supporting the recommendations when explicit recommendations are 
offered and when the references are supplied with those explicit recommendations. This field opens in a 
new window. Links are provided to PubMed where applicable.
Type of Evidence Supporting the 
Recommendations
Describes the type of evidence supporting the recommendations.
Benefits/Harms of Implementing the Recommendations
Potential Benefits Describes the anticipated benefits associated with implementing the guideline's recommendations, as 
stated in the guideline text, to target populations or intended users. Where applicable, the field also 
includes information on the major subgroup(s) of patients within the target population most likely to 
benefit from the guideline recommendations, as identified by the guideline developer.
Potential Harms Description of the anticipated harms, potential risks or adverse consequences associated with the 
guideline's recommendations, as stated in the guideline text, to target populations or intended users. 
Where identified by the original guideline document, the major subgroup(s) of patients within the target 
population most likely to suffer harm/adverse consequences associated with the guideline 
recommendations will also be described.
Contraindications
Contraindications Identifies the instances (e.g., co -morbidities), as provided by the guideline developers, which might 
render the use of medications or procedures improper, undesirable, or inadvisable.
Qualifying Statements
Qualifying Statements Presents qualifying statements or important caveats pertaining to the major recommendations of the 
guideline emphasized by the guideline developer. Identifies the area of uncertainty and presents a brief 
description of how the guideline developer addressed this uncertainty in developing the major 
recommendations of the guideline.
Only caveats pertaining to the major recommendations are included. This attribute may also present 
information regarding uncertainty or controversies in the field identified by the guideline developer that 
prevents formulation of specific recommendations regarding important aspects within the guideline.
Disclaimer-type statements are also captured in this field.
Implementation of the Guideline
Description of Implementation Strategy Describes specific strategies, aims, performance measures, or plans for implementing the guideline 
recommendations, if presented in the guideline or supplied by the guideline developer.
Implementation Tools Classifies the types of implementation tools provided by the guideline developer to facilitate the 
implementation of their guideline. Values are selected from the appropriate concepts in the Classification 
Scheme
Related NQMC Measures Identifies link(s) to related quality measures or measure sets in the National Quality Measures 
Institute of Medicine (IOM) National Healthcare Quality Report Categories
IOM Care Need Classifies the guideline into one of four Institute of Medicine (IOM) care need classifications: End of life 
care; Getting better; Living with illness; Staying healthy.
IOM Domain Classifies the guideline into one or more of the four Institute of Medicine (IOM) care domains: 
Effectiveness; Patient -centeredness; Safety; Timeliness.
Identifying Information and Availability
Bibliographic Source(s) Identifies the complete bibliographic source(s) for the published guideline as disseminated by the guideline 
developer(s). The number of references cited is included for each source. Links are provided to PubMed 
where applicable.
Adaptation Identifies that the guideline has been adapted from another guideline and identifies the source 
document.
Date Released Identifies the date the guideline was released to the public.
Guideline Developer(s) Identifies the organization(s) responsible for the development of the guideline. Each organization is 
classified by the major designation or function (derived from the Organization Type attribute), such as 
"Medical Specialty Society" or "Professional Association."
Guideline Developer Comment If the guideline developer is a consortium or represents a group of organizations, this attribute identifies 
the individual organizations by name.
Source(s) of Funding Identifies source(s) of financial support for guideline development, as identified in the guideline text or by 
the guideline developer. Lists any grant numbers associated with funding, as identified in the guideline 
text or by the guideline developer.
Guideline Committee Identifies formal name, if any, of committee/subcommittee within the guideline developer organization(s) 
responsible for developing the guideline.
Composition of Group That Authored the 
Guideline
Describes the composition of the group/committee that authored the guideline, including professional 
degrees and affiliations, and lists the names of individual committee members, where given.
Financial Disclosures/Conflicts of Interest Captures relationships between individuals of the guideline development committee/group and for -profit 
and not-for-profit companies or organizations that could potentially influence that individual's contribution 
to the guideline's development.
Endorser(s) Identifies organization(s) that have endorsed the guideline, as identified in the text of the guideline 
document or explicitly by the guideline developer. Each organization is classified by the major designation 
or function (derived from the Organization Type attribute), such as "Medical Specialty Society" or 
"Professional Association."
Guideline Status Identifies whether the guideline is a revised or updated version of a previously issued document as well as 
whether an update is currently in progress.
Guideline Availability Identifies information about the availability of the guideline. Provides, where possible, information 
regarding electronic (including hypertext links to the full -text) copies and ordering information for print 
copies.
Availability of Companion Documents Identifies the companion documents produced by the guideline developer that are considered relevant to 
the guideline. These companion documents are not necessarily available within NGC. 
For example, Quick Reference Guides and Technical Reports , all of which would be listed here, accompany 
guidelines produced by the Agency for Healthcare Research and Quality (AHRQ) (formerly the Agency for 
Health Care Policy and Research [AHCPR]).
Patient Resources Identifies patient resources that are directly related (i.e., derived and/or prepared from the guideline by 
the guideline developer) to the guideline included in NGC. The patient information is not reviewed by NGC 
to establish whether or not it accurately reflects the original guideline's content.
NGC Status Identifies when the guideline was completed or revised by ECRI Institute, and verified by the submitting 
organization(s).
Copyright Statement Provides the copyright statement of the organization that submitted the guideline.
Disclaimer
Disclaimer Provides disclaimer information about the relationship between NGC (including its sponsor, the Agency for 
Healthcare Research and Quality (AHRQ), and its contractor, ECRI Institute) and the guidelines and 
guideline developers represented on the Web site. 
Age of the Target 
Population
Describes the age group(s) represented by the target population, enabling users to restrict their searches to a particular age 
group(s).
Sex of the Target 
Population
Classifies the sex(es) represented by the target population, enabling users to restrict their searches to a particular gender.
Disease/Condition(s) NGC uses Medical Subject Headings (MeSH) produced by the U.S. National Library of Medicine (NLM)  , along with other 
controlled vocabularies, such as the International Classification of Diseases (ICD), incorporated into NLM's Unified Medical 
Language System (UMLS)   to classify disease concepts related to NGC guidelines.
Treatment/Intervention NGC uses Medical Subject Headings (MeSH) produced by the U.S. National Library of Medicine (NLM)  , along with other 
controlled vocabularies, such as the U.S. Health Care Financing Administration (HCFA) Common Procedure Coding System and ECRI
Institute's Universal Medical Device Nomenclature System (UMDNS), incorporated into NLM's Unified Medical Language System 
(UMLS)  to classify treatment/intervention concepts related to NGC guidelines.
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Guideline Summary NGC-8840 
Guideline Title
Best evidence statement (BESt). Confirmation of nasogastric/orogastric tube (NGT/OGT) placement.
Bibliographic Source(s)
Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Confirmation of nasogastric/orogastric 
tube (NGT/OGT) placement. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2011 Aug 22. 9 p. [25 
references]
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). 
Confirmation of nasogastric tube placement in pediatric patients. Cincinnati (OH): Cincinnati Children's Hospital Medical 
Center; 2009 Apr 27. 11 p. [20 references]
 
 
 
Scope
Disease/Condition(s)
Conditions in pediatric and adolescent patients that require a nasogastric/orogastric tube (NGT/OGT)
Guideline Category
Assessment of Therapeutic Effectiveness
Evaluation
Clinical Specialty
Critical Care
Pediatrics
Radiology
Intended Users
Advanced Practice Nurses
Nurses
Physician Assistants
Physicians
Guideline Objective(s)
auscultation, acidity (pH), enzyme, visual inspection of aspirate, and carbon dioxide (CO 2) testing compared to 
radiological verification provides an accurate confirmation of tube placement. 
-related 
height-based (ARHB) methods compared to nose -ear-xiphoid (NEX) morphological measurements are more accurate in 
predicting tube length. 
Target Population
Pediatric patients who require nasogastric/orogastric tube (NGT/OGT) placement for feeding or gastric decompression
Interventions and Practices Considered
1.
2) monitoring 
 
2.
-related height-based methods  
-ear-xiphoid (NEX) and nose -ear-mid-xiphoid-umbilicus (NEMU)  
Major Outcomes Considered
-rays  
 
 
 
 
 
Methodology
Methods Used to Collect/Select the Evidence
Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases
Description of Methods Used to Collect/Select the Evidence
OVID Databases
OVID Filters
Search Terms and MeSH Terms
-related height based, 
accuracy, prediction, length. 
Additional articles identified from reference lists and clinicians.
Number of Source Documents
Not stated
Methods Used to Assess the Quality and Strength of the Evidence
Weighting According to a Rating Scheme (Scheme Given)
Rating Scheme for the Strength of the Evidence
Table of Evidence Levels
a = good quality study; b = lesser quality study
 
Quality Level Definition
1a  or 1b Systematic review, meta -analysis, or meta-synthesis of multiple studies
2a or 2b Best study design for domain
3a or 3b Fair study design for domain
4a or 4b Weak study design for domain
5 Other: general review, expert opinion, case report, consensus report, or guideline
Methods Used to Analyze the Evidence
Systematic Review with Evidence Tables
Description of the Methods Used to Analyze the Evidence
Not stated
Methods Used to Formulate the Recommendations
Expert Consensus
Description of Methods Used to Formulate the Recommendations
Not stated
Rating Scheme for the Strength of the Recommendations
Table of Recommendation Strength
Strength Definition
"Strongly recommended" There is consensus that benefits clearly outweigh risks and burdens (or vice versa for negative recommendations).
"Recommended" There is consensus that benefits are closely balanced with risks and burdens.
No recommendation made There is a lack of consensus to direct development of a recommendation.
Dimensions: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that 
incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.
1.
2.
3.
4.  
5. -effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite 
analysis) 
6.
outcome]) 
7.
Cost Analysis
A formal cost analysis was not performed and published cost analyses were not reviewed.
Method of Guideline Validation
Peer Review
Description of Method of Guideline Validation
Reviewed against quality criteria by two independent reviewers.
Recommendations
Major Recommendations
The strength of the recommendation (strongly recommended, recommended, or no recommendation) and the quality of 
the evidence (1a 5) are defined at the end of the "Major Recommendations" field.  
1.
placement in pediatric patients who are at high risk of aspiration or when non -radiologic methods are not feasible, or 
results are unclear. 
Note: Pediatric patients at risk for incorrect tube placement include those who have neurologic impairment and other 
conditions which may increase the difficulty of safe, effective tube placement and include patients who are obtunded, 
sedated, unconscious, critically ill and those with reduced gag reflex or static encephalopathy (Metheny et al., 
"Techniques," 1994 [3a]; Phang et al., 2004 [3b]; Ellett & Beckstrand, 1999 [4b]).
Note: Radiologic verification is considered the gold standard but may contribute to higher costs, decreased 
convenience, and increased radiation exposure (Metheny et al., "Techniques," 1994 [3a]; Metheny & Stewart, 2002 
[3a]; Nyqvist, Sorell, & Ewald, 2005 [4a]; Peter & Gill, 2009 [4a]; Ellett & Beckstrand, 1999 [4b]; Westhus, 2004 
[4b]).
2. -radiological verification methods be used to confirm placement of NGT/OGT in 
pediatric patients who are not considered at high risk for aspiration as outlined above, using the following method: 
al., "Indicators," 1999 [4a]; Metheny & Stewart, 2002 [3a]; Metheny et al., "pH," 1999 [4a]; Metheny et al., 1993 
[3a]) (see Table 1 in the original guideline document).
Note: Gastric aspirate pH mean is statistically lower (higher acidity) compared to intestinal aspirate mean pH 
(Metheny et al., "pH," 1999 [4a]).
Note: Mean pH of respiratory aspirate from the tracheobroncheal tree or plural space is statistically higher than 
gastric aspirate pH (Metheny et al., "pH," 1999 [4a]).
Note: pH testing can be accurately done with pH paper or pH meter (Ellet et al., 2005 [3a]; Metheny et al., "pH," 
1994 [3a]; Westhus, 2004 [4b]).
Note: Mean values for gastric aspirate are not significantly different when patients are fed or fasting (Metheny & 
Stewart, 2002 [3a]; Metheny et al., "pH and concentration," 1999 [4a]).
Note: Mean values for aspirate are not significantly different when patients are on or off acid suppression medications
(Ellett et al., 2005 [3a]; Metheny et al., "pH," 1994 [3a]).
Note: Auscultation has been shown to have poor reliability and is not recommended as a sole verification method. 
(Ellett & Beckstrand, 1999 [4b]; Metheny & Stewart, 2002 [3a]; Metheny et al., 1990 [4a]; Neumann et al., 1995 
[3b]).
Note: Visual inspection of aspirate has not been shown to be a reliable sole method of verification; however, it may 
have some use when done in conjunction with pH testing (Garpure et al., 2000 [4a]; Metheny & Stewart, 2002 [3a]; 
Metheny et al., "Indicators," 1999 [4a]; Metheny et al., "Techniques," 1994 [3a]; Metheny et al., "Visual," 1994 [4a]; 
Phang et al., 2004 [3b]; Westhus, 2004 [4b]).
Note: Aspirate testing of enzyme levels for bilirubin, pepsin, and trypsin also provide an alternate method of 
verification, but it is limited to laboratory assessment (Ellett et al., 2005 [3a]; Garpure et al., 2000 [4a]; Metheny & 
Stewart, 2002 [3a]; Metheny et al., "pH and concentration," 1999 [4a]; Westhus, 2004 [4b]).
Note: While carbon dioxide (CO 2) monitoring provides an alternate method of verification, it requires a capnograph 
monitor to determine incorrect tube placement (Ellett et al., 2005 [3a]).
3.
For children >2 weeks, age -related height-based (ARHB) methods are more accurate than other morphological 
measures such as nose -ear-xiphoid (NEX) or nose -ear-mid-xiphoid-umbilicus (NEMU) in predicting tube length and can 
be calculated using prediction equation tables (see Table below: Age -related height-based equations for nasogastric 
tube [NGT] length predictions) (Beckstrand, Ellett, & McDaniel, 2007 [4a]; Ellett et al., 1992 [4b]; Klasner, Luke, & 
Scalzo, 2002 [2b]; Putnam & Orenstein, 1991 [4a]; Strobel et al., 1979 [4b]).
For neonates less than 2 weeks of age, patients with short stature, or if unable to obtain an accurate height, use 
morphological measurements such as NEX or NEMU (Beckstrand, Ellett, & McDaniel, 2007 [4a]).
Note: Measurement using the NEMU method for tube length prediction versus the NEX method is slightly more 
reliable for tube length prediction (Beckstrand, Ellett, & McDaniel, 2007 [4a]; Gallaher et al., 1993 [3a]; Weibley et 
al., 1987 [4a]).
Note: Short stature is defined as a standing height more than 2 standard deviations (SDs) below the mean (or below 
the 2.5 percentile) for sex (Cohen et al., 2008 [5]).
Note: Mark tube length at the nare for NGT, or corner of the mouth for OGT with indelible permanent marker and 
document amount of tube remaining (external visible length) (EVL) outside the patient in the patient record (Weibley 
et al., 1987 [4a]).
Table: Age-related Height-based (ARHB) Prediction Equations for the Internal Distance to the Body of the Stomach
for Use in Clinical Practice, by Route of Insertion and Age in Children
Note: the distance measured is to the bottom of the distal pore on the tube Beckstrand, (2007) [4a] Used with permission.  
See Figure 1 in the original guideline document for Algorithm: Confirmation of NGT/OGT Placement.
Definitions:
Table of Evidence Levels
a = good quality study; b = lesser quality study
 
Table of Recommendation Strength
Route Age Group (months) Predicted Internal Distance to the Body of the Stomach
Oral 9.1 cm + 0.183 (height cm) + 6 cm + 1.5 cm = 16.6 + 0.183 (height cm)
9.1 cm + 0.183 (height cm) + 8 cm + 3 cm = 20.1 + 0.183 (height cm)
4.5 cm + 0.218 (height cm) + 7.5 cm + 5 cm = 17 + 0.218 (height cm)
Age >121 4. 5cm + 0.218 (height cm) + 9 cm + 5 cm = 18.5 + 0.218 (height cm)
Nasal Age <28 10.1 cm + 0.197 (height cm) + 6 cm + 1.5 cm = 17.6 + 0.197 (height cm)
28 < age < 100 10.1 cm + 0.197 (height cm) + 8 cm + 3 cm = 21.1 + 0.197 (height cm)
100 < age < 121 4.5 cm + (2.7) + 0.218 (height cm) + 6.5 cm + 5 cm = 18.7 + 0.218 (height cm)
Age >121 4.5 cm + (2.7) + 0.218 (height cm) + 9 cm + 5 cm = 21.2 + 0.218 (height cm)
Quality Level Definition
1a  or 1b Systematic review, meta -analysis, or meta-synthesis of multiple studies
2a or 2b Best study design for domain
3a or 3b Fair study design for domain
4a or 4b Weak study design for domain
5 Other: general review, expert opinion, case report, consensus report, or guideline
Strength Definition
"Strongly recommended" There is consensus that benefits clearly outweigh risks and burdens (or vice versa for negative recommendations).
"Recommended" There is consensus that benefits are closely balanced with risks and burdens.
No recommendation made There is a lack of consensus to direct development of a recommendation.
Dimensions: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that 
incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.
1.
2.
3.
4.  
5. -effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite 
analysis) 
6.
outcome]) 
7.
Clinical Algorithm(s)
A clinical algorithm for the confirmation of nasogastric or orogastric tube (NGT/ORT) placement is provided in the original 
guideline document.
Evidence Supporting the Recommendations
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-4. PubMed 
Putnam PE, Orenstein SR. Determining esophageal length from crown -
Nov;13(4):354-9. PubMed 
Strobel CT, Byrne WJ, Ament ME, Euler AR. Correlation of esophageal lengths in children with height: application to the 
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Type of Evidence Supporting the Recommendations
The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" 
field).
Benefits/Harms of Implementing the Guideline Recommendations
Potential Benefits
-
radiological methods 
-radiological NGT/OGT placement methods contribute to decreased radiation exposure for pediatric patients.  
may contribute to decreased costs. 
Potential Harms
Qualifying Statements
Qualifying Statements
This Best Evidence Statement addresses only key points of care for the target population; it is not intended to be a 
comprehensive practice guideline. These recommendations result from review of literature and practices current at the 
time of their formulation. This Best Evidence Statement does not preclude using care modalities proven efficacious in 
studies published subsequent to the current revision of this document. This document is not intended to impose 
standards of care preventing selective variances from the recommendations to meet the specific and unique requirements 
of individual patients. Adherence to this Statement is voluntary. The clinician in light of the individual circumstances 
presented by the patient must make the ultimate judgment regarding the priority of any specific procedure.
Implementation of the Guideline
Description of Implementation Strategy
An implementation strategy was not provided.
Implementation Tools
Clinical Algorithm
For information about availability, see the Availability of Companion Documents  and Patient Resources  fields below.
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references]
Guideline Status
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Scope
Disease/Condition(s)
Conditions in pediatric and adolescent patients that require a nasogastric/orogastric tube (NGT/OGT)
Guideline Category
Assessment of Therapeutic Effectiveness
Evaluation
Clinical Specialty
Critical Care
Pediatrics
Radiology
Intended Users
Advanced Practice Nurses
Nurses
Physician Assistants
Physicians
Guideline Objective(s)
auscultation, acidity (pH), enzyme, visual inspection of aspirate, and carbon dioxide (CO 2) testing compared to 
radiological verification provides an accurate confirmation of tube placement. 
-related 
height-based (ARHB) methods compared to nose -ear-xiphoid (NEX) morphological measurements are more accurate in 
predicting tube length. 
Target Population
Pediatric patients who require nasogastric/orogastric tube (NGT/OGT) placement for feeding or gastric decompression
Interventions and Practices Considered
1.
2) monitoring 
 
2.
-related height-based methods  
-ear-xiphoid (NEX) and nose -ear-mid-xiphoid-umbilicus (NEMU)  
Major Outcomes Considered
-rays  
 
 
 
 
 
Methodology
Methods Used to Collect/Select the Evidence
Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases
Description of Methods Used to Collect/Select the Evidence
OVID Databases
OVID Filters
Search Terms and MeSH Terms
-related height based, 
accuracy, prediction, length. 
Additional articles identified from reference lists and clinicians.
Number of Source Documents
Not stated
Methods Used to Assess the Quality and Strength of the Evidence
Weighting According to a Rating Scheme (Scheme Given)
Rating Scheme for the Strength of the Evidence
Table of Evidence Levels
a = good quality study; b = lesser quality study
 
Quality Level Definition
1a  or 1b Systematic review, meta -analysis, or meta-synthesis of multiple studies
2a or 2b Best study design for domain
3a or 3b Fair study design for domain
4a or 4b Weak study design for domain
5 Other: general review, expert opinion, case report, consensus report, or guideline
Methods Used to Analyze the Evidence
Systematic Review with Evidence Tables
Description of the Methods Used to Analyze the Evidence
Not stated
Methods Used to Formulate the Recommendations
Expert Consensus
Description of Methods Used to Formulate the Recommendations
Not stated
Rating Scheme for the Strength of the Recommendations
Table of Recommendation Strength
Strength Definition
"Strongly recommended" There is consensus that benefits clearly outweigh risks and burdens (or vice versa for negative recommendations).
"Recommended" There is consensus that benefits are closely balanced with risks and burdens.
No recommendation made There is a lack of consensus to direct development of a recommendation.
Dimensions: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that 
incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.
1.
2.
3.
4.  
5. -effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite 
analysis) 
6.
outcome]) 
7.
Cost Analysis
A formal cost analysis was not performed and published cost analyses were not reviewed.
Method of Guideline Validation
Peer Review
Description of Method of Guideline Validation
Reviewed against quality criteria by two independent reviewers.
Recommendations
Major Recommendations
The strength of the recommendation (strongly recommended, recommended, or no recommendation) and the quality of 
the evidence (1a 5) are defined at the end of the "Major Recommendations" field.  
1.
placement in pediatric patients who are at high risk of aspiration or when non -radiologic methods are not feasible, or 
results are unclear. 
Note: Pediatric patients at risk for incorrect tube placement include those who have neurologic impairment and other 
conditions which may increase the difficulty of safe, effective tube placement and include patients who are obtunded, 
sedated, unconscious, critically ill and those with reduced gag reflex or static encephalopathy (Metheny et al., 
"Techniques," 1994 [3a]; Phang et al., 2004 [3b]; Ellett & Beckstrand, 1999 [4b]).
Note: Radiologic verification is considered the gold standard but may contribute to higher costs, decreased 
convenience, and increased radiation exposure (Metheny et al., "Techniques," 1994 [3a]; Metheny & Stewart, 2002 
[3a]; Nyqvist, Sorell, & Ewald, 2005 [4a]; Peter & Gill, 2009 [4a]; Ellett & Beckstrand, 1999 [4b]; Westhus, 2004 
[4b]).
2. -radiological verification methods be used to confirm placement of NGT/OGT in 
pediatric patients who are not considered at high risk for aspiration as outlined above, using the following method: 
al., "Indicators," 1999 [4a]; Metheny & Stewart, 2002 [3a]; Metheny et al., "pH," 1999 [4a]; Metheny et al., 1993 
[3a]) (see Table 1 in the original guideline document).
Note: Gastric aspirate pH mean is statistically lower (higher acidity) compared to intestinal aspirate mean pH 
(Metheny et al., "pH," 1999 [4a]).
Note: Mean pH of respiratory aspirate from the tracheobroncheal tree or plural space is statistically higher than 
gastric aspirate pH (Metheny et al., "pH," 1999 [4a]).
Note: pH testing can be accurately done with pH paper or pH meter (Ellet et al., 2005 [3a]; Metheny et al., "pH," 
1994 [3a]; Westhus, 2004 [4b]).
Note: Mean values for gastric aspirate are not significantly different when patients are fed or fasting (Metheny & 
Stewart, 2002 [3a]; Metheny et al., "pH and concentration," 1999 [4a]).
Note: Mean values for aspirate are not significantly different when patients are on or off acid suppression medications
(Ellett et al., 2005 [3a]; Metheny et al., "pH," 1994 [3a]).
Note: Auscultation has been shown to have poor reliability and is not recommended as a sole verification method. 
(Ellett & Beckstrand, 1999 [4b]; Metheny & Stewart, 2002 [3a]; Metheny et al., 1990 [4a]; Neumann et al., 1995 
[3b]).
Note: Visual inspection of aspirate has not been shown to be a reliable sole method of verification; however, it may 
have some use when done in conjunction with pH testing (Garpure et al., 2000 [4a]; Metheny & Stewart, 2002 [3a]; 
Metheny et al., "Indicators," 1999 [4a]; Metheny et al., "Techniques," 1994 [3a]; Metheny et al., "Visual," 1994 [4a]; 
Phang et al., 2004 [3b]; Westhus, 2004 [4b]).
Note: Aspirate testing of enzyme levels for bilirubin, pepsin, and trypsin also provide an alternate method of 
verification, but it is limited to laboratory assessment (Ellett et al., 2005 [3a]; Garpure et al., 2000 [4a]; Metheny & 
Stewart, 2002 [3a]; Metheny et al., "pH and concentration," 1999 [4a]; Westhus, 2004 [4b]).
Note: While carbon dioxide (CO 2) monitoring provides an alternate method of verification, it requires a capnograph 
monitor to determine incorrect tube placement (Ellett et al., 2005 [3a]).
3.
For children >2 weeks, age -related height-based (ARHB) methods are more accurate than other morphological 
measures such as nose -ear-xiphoid (NEX) or nose -ear-mid-xiphoid-umbilicus (NEMU) in predicting tube length and can 
be calculated using prediction equation tables (see Table below: Age -related height-based equations for nasogastric 
tube [NGT] length predictions) (Beckstrand, Ellett, & McDaniel, 2007 [4a]; Ellett et al., 1992 [4b]; Klasner, Luke, & 
Scalzo, 2002 [2b]; Putnam & Orenstein, 1991 [4a]; Strobel et al., 1979 [4b]).
For neonates less than 2 weeks of age, patients with short stature, or if unable to obtain an accurate height, use 
morphological measurements such as NEX or NEMU (Beckstrand, Ellett, & McDaniel, 2007 [4a]).
Note: Measurement using the NEMU method for tube length prediction versus the NEX method is slightly more 
reliable for tube length prediction (Beckstrand, Ellett, & McDaniel, 2007 [4a]; Gallaher et al., 1993 [3a]; Weibley et 
al., 1987 [4a]).
Note: Short stature is defined as a standing height more than 2 standard deviations (SDs) below the mean (or below 
the 2.5 percentile) for sex (Cohen et al., 2008 [5]).
Note: Mark tube length at the nare for NGT, or corner of the mouth for OGT with indelible permanent marker and 
document amount of tube remaining (external visible length) (EVL) outside the patient in the patient record (Weibley 
et al., 1987 [4a]).
Table: Age-related Height-based (ARHB) Prediction Equations for the Internal Distance to the Body of the Stomach
for Use in Clinical Practice, by Route of Insertion and Age in Children
Note: the distance measured is to the bottom of the distal pore on the tube Beckstrand, (2007) [4a] Used with permission.  
See Figure 1 in the original guideline document for Algorithm: Confirmation of NGT/OGT Placement.
Definitions:
Table of Evidence Levels
a = good quality study; b = lesser quality study
 
Table of Recommendation Strength
Route Age Group (months) Predicted Internal Distance to the Body of the Stomach
Oral 9.1 cm + 0.183 (height cm) + 6 cm + 1.5 cm = 16.6 + 0.183 (height cm)
9.1 cm + 0.183 (height cm) + 8 cm + 3 cm = 20.1 + 0.183 (height cm)
4.5 cm + 0.218 (height cm) + 7.5 cm + 5 cm = 17 + 0.218 (height cm)
Age >121 4. 5cm + 0.218 (height cm) + 9 cm + 5 cm = 18.5 + 0.218 (height cm)
Nasal Age <28 10.1 cm + 0.197 (height cm) + 6 cm + 1.5 cm = 17.6 + 0.197 (height cm)
28 < age < 100 10.1 cm + 0.197 (height cm) + 8 cm + 3 cm = 21.1 + 0.197 (height cm)
100 < age < 121 4.5 cm + (2.7) + 0.218 (height cm) + 6.5 cm + 5 cm = 18.7 + 0.218 (height cm)
Age >121 4.5 cm + (2.7) + 0.218 (height cm) + 9 cm + 5 cm = 21.2 + 0.218 (height cm)
Quality Level Definition
1a  or 1b Systematic review, meta -analysis, or meta-synthesis of multiple studies
2a or 2b Best study design for domain
3a or 3b Fair study design for domain
4a or 4b Weak study design for domain
5 Other: general review, expert opinion, case report, consensus report, or guideline
Strength Definition
"Strongly recommended" There is consensus that benefits clearly outweigh risks and burdens (or vice versa for negative recommendations).
"Recommended" There is consensus that benefits are closely balanced with risks and burdens.
No recommendation made There is a lack of consensus to direct development of a recommendation.
Dimensions: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that 
incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.
1.
2.
3.
4.  
5. -effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite 
analysis) 
6.
outcome]) 
7.
Clinical Algorithm(s)
A clinical algorithm for the confirmation of nasogastric or orogastric tube (NGT/ORT) placement is provided in the original 
guideline document.
Evidence Supporting the Recommendations
References Supporting the Recommendations
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Type of Evidence Supporting the Recommendations
The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" 
field).
Benefits/Harms of Implementing the Guideline Recommendations
Potential Benefits
-
radiological methods 
-radiological NGT/OGT placement methods contribute to decreased radiation exposure for pediatric patients.  
may contribute to decreased costs. 
Potential Harms
Qualifying Statements
Qualifying Statements
This Best Evidence Statement addresses only key points of care for the target population; it is not intended to be a 
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Cincinnati Children's Hospital Medical Center. Best evidence statement (BESt). Confirmation of nasogastric/orogastric 
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Guideline Status
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Scope
Disease/Condition(s)
Conditions in pediatric and adolescent patients that require a nasogastric/orogastric tube (NGT/OGT)
Guideline Category
Assessment of Therapeutic Effectiveness
Evaluation
Clinical Specialty
Critical Care
Pediatrics
Radiology
Intended Users
Advanced Practice Nurses
Nurses
Physician Assistants
Physicians
Guideline Objective(s)
auscultation, acidity (pH), enzyme, visual inspection of aspirate, and carbon dioxide (CO 2) testing compared to 
radiological verification provides an accurate confirmation of tube placement. 
-related 
height-based (ARHB) methods compared to nose -ear-xiphoid (NEX) morphological measurements are more accurate in 
predicting tube length. 
Target Population
Pediatric patients who require nasogastric/orogastric tube (NGT/OGT) placement for feeding or gastric decompression
Interventions and Practices Considered
1.
2) monitoring 
 
2.
-related height-based methods  
-ear-xiphoid (NEX) and nose -ear-mid-xiphoid-umbilicus (NEMU)  
Major Outcomes Considered
-rays  
 
 
 
 
 
Methodology
Methods Used to Collect/Select the Evidence
Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases
Description of Methods Used to Collect/Select the Evidence
OVID Databases
OVID Filters
Search Terms and MeSH Terms
-related height based, 
accuracy, prediction, length. 
Additional articles identified from reference lists and clinicians.
Number of Source Documents
Not stated
Methods Used to Assess the Quality and Strength of the Evidence
Weighting According to a Rating Scheme (Scheme Given)
Rating Scheme for the Strength of the Evidence
Table of Evidence Levels
a = good quality study; b = lesser quality study
 
Quality Level Definition
1a  or 1b Systematic review, meta -analysis, or meta-synthesis of multiple studies
2a or 2b Best study design for domain
3a or 3b Fair study design for domain
4a or 4b Weak study design for domain
5 Other: general review, expert opinion, case report, consensus report, or guideline
Methods Used to Analyze the Evidence
Systematic Review with Evidence Tables
Description of the Methods Used to Analyze the Evidence
Not stated
Methods Used to Formulate the Recommendations
Expert Consensus
Description of Methods Used to Formulate the Recommendations
Not stated
Rating Scheme for the Strength of the Recommendations
Table of Recommendation Strength
Strength Definition
"Strongly recommended" There is consensus that benefits clearly outweigh risks and burdens (or vice versa for negative recommendations).
"Recommended" There is consensus that benefits are closely balanced with risks and burdens.
No recommendation made There is a lack of consensus to direct development of a recommendation.
Dimensions: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that 
incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.
1.
2.
3.
4.  
5. -effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite 
analysis) 
6.
outcome]) 
7.
Cost Analysis
A formal cost analysis was not performed and published cost analyses were not reviewed.
Method of Guideline Validation
Peer Review
Description of Method of Guideline Validation
Reviewed against quality criteria by two independent reviewers.
Recommendations
Major Recommendations
The strength of the recommendation (strongly recommended, recommended, or no recommendation) and the quality of 
the evidence (1a 5) are defined at the end of the "Major Recommendations" field.  
1.
placement in pediatric patients who are at high risk of aspiration or when non -radiologic methods are not feasible, or 
results are unclear. 
Note: Pediatric patients at risk for incorrect tube placement include those who have neurologic impairment and other 
conditions which may increase the difficulty of safe, effective tube placement and include patients who are obtunded, 
sedated, unconscious, critically ill and those with reduced gag reflex or static encephalopathy (Metheny et al., 
"Techniques," 1994 [3a]; Phang et al., 2004 [3b]; Ellett & Beckstrand, 1999 [4b]).
Note: Radiologic verification is considered the gold standard but may contribute to higher costs, decreased 
convenience, and increased radiation exposure (Metheny et al., "Techniques," 1994 [3a]; Metheny & Stewart, 2002 
[3a]; Nyqvist, Sorell, & Ewald, 2005 [4a]; Peter & Gill, 2009 [4a]; Ellett & Beckstrand, 1999 [4b]; Westhus, 2004 
[4b]).
2. -radiological verification methods be used to confirm placement of NGT/OGT in 
pediatric patients who are not considered at high risk for aspiration as outlined above, using the following method: 
al., "Indicators," 1999 [4a]; Metheny & Stewart, 2002 [3a]; Metheny et al., "pH," 1999 [4a]; Metheny et al., 1993 
[3a]) (see Table 1 in the original guideline document).
Note: Gastric aspirate pH mean is statistically lower (higher acidity) compared to intestinal aspirate mean pH 
(Metheny et al., "pH," 1999 [4a]).
Note: Mean pH of respiratory aspirate from the tracheobroncheal tree or plural space is statistically higher than 
gastric aspirate pH (Metheny et al., "pH," 1999 [4a]).
Note: pH testing can be accurately done with pH paper or pH meter (Ellet et al., 2005 [3a]; Metheny et al., "pH," 
1994 [3a]; Westhus, 2004 [4b]).
Note: Mean values for gastric aspirate are not significantly different when patients are fed or fasting (Metheny & 
Stewart, 2002 [3a]; Metheny et al., "pH and concentration," 1999 [4a]).
Note: Mean values for aspirate are not significantly different when patients are on or off acid suppression medications
(Ellett et al., 2005 [3a]; Metheny et al., "pH," 1994 [3a]).
Note: Auscultation has been shown to have poor reliability and is not recommended as a sole verification method. 
(Ellett & Beckstrand, 1999 [4b]; Metheny & Stewart, 2002 [3a]; Metheny et al., 1990 [4a]; Neumann et al., 1995 
[3b]).
Note: Visual inspection of aspirate has not been shown to be a reliable sole method of verification; however, it may 
have some use when done in conjunction with pH testing (Garpure et al., 2000 [4a]; Metheny & Stewart, 2002 [3a]; 
Metheny et al., "Indicators," 1999 [4a]; Metheny et al., "Techniques," 1994 [3a]; Metheny et al., "Visual," 1994 [4a]; 
Phang et al., 2004 [3b]; Westhus, 2004 [4b]).
Note: Aspirate testing of enzyme levels for bilirubin, pepsin, and trypsin also provide an alternate method of 
verification, but it is limited to laboratory assessment (Ellett et al., 2005 [3a]; Garpure et al., 2000 [4a]; Metheny & 
Stewart, 2002 [3a]; Metheny et al., "pH and concentration," 1999 [4a]; Westhus, 2004 [4b]).
Note: While carbon dioxide (CO 2) monitoring provides an alternate method of verification, it requires a capnograph 
monitor to determine incorrect tube placement (Ellett et al., 2005 [3a]).
3.
For children >2 weeks, age -related height-based (ARHB) methods are more accurate than other morphological 
measures such as nose -ear-xiphoid (NEX) or nose -ear-mid-xiphoid-umbilicus (NEMU) in predicting tube length and can 
be calculated using prediction equation tables (see Table below: Age -related height-based equations for nasogastric 
tube [NGT] length predictions) (Beckstrand, Ellett, & McDaniel, 2007 [4a]; Ellett et al., 1992 [4b]; Klasner, Luke, & 
Scalzo, 2002 [2b]; Putnam & Orenstein, 1991 [4a]; Strobel et al., 1979 [4b]).
For neonates less than 2 weeks of age, patients with short stature, or if unable to obtain an accurate height, use 
morphological measurements such as NEX or NEMU (Beckstrand, Ellett, & McDaniel, 2007 [4a]).
Note: Measurement using the NEMU method for tube length prediction versus the NEX method is slightly more 
reliable for tube length prediction (Beckstrand, Ellett, & McDaniel, 2007 [4a]; Gallaher et al., 1993 [3a]; Weibley et 
al., 1987 [4a]).
Note: Short stature is defined as a standing height more than 2 standard deviations (SDs) below the mean (or below 
the 2.5 percentile) for sex (Cohen et al., 2008 [5]).
Note: Mark tube length at the nare for NGT, or corner of the mouth for OGT with indelible permanent marker and 
document amount of tube remaining (external visible length) (EVL) outside the patient in the patient record (Weibley 
et al., 1987 [4a]).
Table: Age-related Height-based (ARHB) Prediction Equations for the Internal Distance to the Body of the Stomach
for Use in Clinical Practice, by Route of Insertion and Age in Children
Note: the distance measured is to the bottom of the distal pore on the tube Beckstrand, (2007) [4a] Used with permission.  
See Figure 1 in the original guideline document for Algorithm: Confirmation of NGT/OGT Placement.
Definitions:
Table of Evidence Levels
a = good quality study; b = lesser quality study
 
Table of Recommendation Strength
Route Age Group (months) Predicted Internal Distance to the Body of the Stomach
Oral 9.1 cm + 0.183 (height cm) + 6 cm + 1.5 cm = 16.6 + 0.183 (height cm)
9.1 cm + 0.183 (height cm) + 8 cm + 3 cm = 20.1 + 0.183 (height cm)
4.5 cm + 0.218 (height cm) + 7.5 cm + 5 cm = 17 + 0.218 (height cm)
Age >121 4. 5cm + 0.218 (height cm) + 9 cm + 5 cm = 18.5 + 0.218 (height cm)
Nasal Age <28 10.1 cm + 0.197 (height cm) + 6 cm + 1.5 cm = 17.6 + 0.197 (height cm)
28 < age < 100 10.1 cm + 0.197 (height cm) + 8 cm + 3 cm = 21.1 + 0.197 (height cm)
100 < age < 121 4.5 cm + (2.7) + 0.218 (height cm) + 6.5 cm + 5 cm = 18.7 + 0.218 (height cm)
Age >121 4.5 cm + (2.7) + 0.218 (height cm) + 9 cm + 5 cm = 21.2 + 0.218 (height cm)
Quality Level Definition
1a  or 1b Systematic review, meta -analysis, or meta-synthesis of multiple studies
2a or 2b Best study design for domain
3a or 3b Fair study design for domain
4a or 4b Weak study design for domain
5 Other: general review, expert opinion, case report, consensus report, or guideline
Strength Definition
"Strongly recommended" There is consensus that benefits clearly outweigh risks and burdens (or vice versa for negative recommendations).
"Recommended" There is consensus that benefits are closely balanced with risks and burdens.
No recommendation made There is a lack of consensus to direct development of a recommendation.
Dimensions: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that 
incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.
1.
2.
3.
4.  
5. -effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite 
analysis) 
6.
outcome]) 
7.
Clinical Algorithm(s)
A clinical algorithm for the confirmation of nasogastric or orogastric tube (NGT/ORT) placement is provided in the original 
guideline document.
Evidence Supporting the Recommendations
References Supporting the Recommendations
Beckstrand J, Cirgin Ellett ML, McDaniel A. Predicting internal distance to the stomach for positioning nasogastric and 
-89. PubMed 
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Metheny NA, Clouse RE, Clark JM, Reed L, Wehrle MA, Wiersema L. pH testing of feeding -tube aspirates to determine 
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-Oct;29(5):282-7; 
quiz 290-1. PubMed 
Type of Evidence Supporting the Recommendations
The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" 
field).
Benefits/Harms of Implementing the Guideline Recommendations
Potential Benefits
-
radiological methods 
-radiological NGT/OGT placement methods contribute to decreased radiation exposure for pediatric patients.  
may contribute to decreased costs. 
Potential Harms
Qualifying Statements
Qualifying Statements
This Best Evidence Statement addresses only key points of care for the target population; it is not intended to be a 
comprehensive practice guideline. These recommendations result from review of literature and practices current at the 
time of their formulation. This Best Evidence Statement does not preclude using care modalities proven efficacious in 
studies published subsequent to the current revision of this document. This document is not intended to impose 
standards of care preventing selective variances from the recommendations to meet the specific and unique requirements 
of individual patients. Adherence to this Statement is voluntary. The clinician in light of the individual circumstances 
presented by the patient must make the ultimate judgment regarding the priority of any specific procedure.
Implementation of the Guideline
Description of Implementation Strategy
An implementation strategy was not provided.
Implementation Tools
Clinical Algorithm
For information about availability, see the Availability of Companion Documents  and Patient Resources  fields below.
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Scope
Disease/Condition(s)
Conditions in pediatric and adolescent patients that require a nasogastric/orogastric tube (NGT/OGT)
Guideline Category
Assessment of Therapeutic Effectiveness
Evaluation
Clinical Specialty
Critical Care
Pediatrics
Radiology
Intended Users
Advanced Practice Nurses
Nurses
Physician Assistants
Physicians
Guideline Objective(s)
auscultation, acidity (pH), enzyme, visual inspection of aspirate, and carbon dioxide (CO 2) testing compared to 
radiological verification provides an accurate confirmation of tube placement. 
-related 
height-based (ARHB) methods compared to nose -ear-xiphoid (NEX) morphological measurements are more accurate in 
predicting tube length. 
Target Population
Pediatric patients who require nasogastric/orogastric tube (NGT/OGT) placement for feeding or gastric decompression
Interventions and Practices Considered
1.
2) monitoring 
 
2.
-related height-based methods  
-ear-xiphoid (NEX) and nose -ear-mid-xiphoid-umbilicus (NEMU)  
Major Outcomes Considered
-rays  
 
 
 
 
 
Methodology
Methods Used to Collect/Select the Evidence
Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases
Description of Methods Used to Collect/Select the Evidence
OVID Databases
OVID Filters
Search Terms and MeSH Terms
-related height based, 
accuracy, prediction, length. 
Additional articles identified from reference lists and clinicians.
Number of Source Documents
Not stated
Methods Used to Assess the Quality and Strength of the Evidence
Weighting According to a Rating Scheme (Scheme Given)
Rating Scheme for the Strength of the Evidence
Table of Evidence Levels
a = good quality study; b = lesser quality study
 
Quality Level Definition
1a  or 1b Systematic review, meta -analysis, or meta-synthesis of multiple studies
2a or 2b Best study design for domain
3a or 3b Fair study design for domain
4a or 4b Weak study design for domain
5 Other: general review, expert opinion, case report, consensus report, or guideline
Methods Used to Analyze the Evidence
Systematic Review with Evidence Tables
Description of the Methods Used to Analyze the Evidence
Not stated
Methods Used to Formulate the Recommendations
Expert Consensus
Description of Methods Used to Formulate the Recommendations
Not stated
Rating Scheme for the Strength of the Recommendations
Table of Recommendation Strength
Strength Definition
"Strongly recommended" There is consensus that benefits clearly outweigh risks and burdens (or vice versa for negative recommendations).
"Recommended" There is consensus that benefits are closely balanced with risks and burdens.
No recommendation made There is a lack of consensus to direct development of a recommendation.
Dimensions: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that 
incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.
1.
2.
3.
4.  
5. -effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite 
analysis) 
6.
outcome]) 
7.
Cost Analysis
A formal cost analysis was not performed and published cost analyses were not reviewed.
Method of Guideline Validation
Peer Review
Description of Method of Guideline Validation
Reviewed against quality criteria by two independent reviewers.
Recommendations
Major Recommendations
The strength of the recommendation (strongly recommended, recommended, or no recommendation) and the quality of 
the evidence (1a 5) are defined at the end of the "Major Recommendations" field.  
1.
placement in pediatric patients who are at high risk of aspiration or when non -radiologic methods are not feasible, or 
results are unclear. 
Note: Pediatric patients at risk for incorrect tube placement include those who have neurologic impairment and other 
conditions which may increase the difficulty of safe, effective tube placement and include patients who are obtunded, 
sedated, unconscious, critically ill and those with reduced gag reflex or static encephalopathy (Metheny et al., 
"Techniques," 1994 [3a]; Phang et al., 2004 [3b]; Ellett & Beckstrand, 1999 [4b]).
Note: Radiologic verification is considered the gold standard but may contribute to higher costs, decreased 
convenience, and increased radiation exposure (Metheny et al., "Techniques," 1994 [3a]; Metheny & Stewart, 2002 
[3a]; Nyqvist, Sorell, & Ewald, 2005 [4a]; Peter & Gill, 2009 [4a]; Ellett & Beckstrand, 1999 [4b]; Westhus, 2004 
[4b]).
2. -radiological verification methods be used to confirm placement of NGT/OGT in 
pediatric patients who are not considered at high risk for aspiration as outlined above, using the following method: 
al., "Indicators," 1999 [4a]; Metheny & Stewart, 2002 [3a]; Metheny et al., "pH," 1999 [4a]; Metheny et al., 1993 
[3a]) (see Table 1 in the original guideline document).
Note: Gastric aspirate pH mean is statistically lower (higher acidity) compared to intestinal aspirate mean pH 
(Metheny et al., "pH," 1999 [4a]).
Note: Mean pH of respiratory aspirate from the tracheobroncheal tree or plural space is statistically higher than 
gastric aspirate pH (Metheny et al., "pH," 1999 [4a]).
Note: pH testing can be accurately done with pH paper or pH meter (Ellet et al., 2005 [3a]; Metheny et al., "pH," 
1994 [3a]; Westhus, 2004 [4b]).
Note: Mean values for gastric aspirate are not significantly different when patients are fed or fasting (Metheny & 
Stewart, 2002 [3a]; Metheny et al., "pH and concentration," 1999 [4a]).
Note: Mean values for aspirate are not significantly different when patients are on or off acid suppression medications
(Ellett et al., 2005 [3a]; Metheny et al., "pH," 1994 [3a]).
Note: Auscultation has been shown to have poor reliability and is not recommended as a sole verification method. 
(Ellett & Beckstrand, 1999 [4b]; Metheny & Stewart, 2002 [3a]; Metheny et al., 1990 [4a]; Neumann et al., 1995 
[3b]).
Note: Visual inspection of aspirate has not been shown to be a reliable sole method of verification; however, it may 
have some use when done in conjunction with pH testing (Garpure et al., 2000 [4a]; Metheny & Stewart, 2002 [3a]; 
Metheny et al., "Indicators," 1999 [4a]; Metheny et al., "Techniques," 1994 [3a]; Metheny et al., "Visual," 1994 [4a]; 
Phang et al., 2004 [3b]; Westhus, 2004 [4b]).
Note: Aspirate testing of enzyme levels for bilirubin, pepsin, and trypsin also provide an alternate method of 
verification, but it is limited to laboratory assessment (Ellett et al., 2005 [3a]; Garpure et al., 2000 [4a]; Metheny & 
Stewart, 2002 [3a]; Metheny et al., "pH and concentration," 1999 [4a]; Westhus, 2004 [4b]).
Note: While carbon dioxide (CO 2) monitoring provides an alternate method of verification, it requires a capnograph 
monitor to determine incorrect tube placement (Ellett et al., 2005 [3a]).
3.
For children >2 weeks, age -related height-based (ARHB) methods are more accurate than other morphological 
measures such as nose -ear-xiphoid (NEX) or nose -ear-mid-xiphoid-umbilicus (NEMU) in predicting tube length and can 
be calculated using prediction equation tables (see Table below: Age -related height-based equations for nasogastric 
tube [NGT] length predictions) (Beckstrand, Ellett, & McDaniel, 2007 [4a]; Ellett et al., 1992 [4b]; Klasner, Luke, & 
Scalzo, 2002 [2b]; Putnam & Orenstein, 1991 [4a]; Strobel et al., 1979 [4b]).
For neonates less than 2 weeks of age, patients with short stature, or if unable to obtain an accurate height, use 
morphological measurements such as NEX or NEMU (Beckstrand, Ellett, & McDaniel, 2007 [4a]).
Note: Measurement using the NEMU method for tube length prediction versus the NEX method is slightly more 
reliable for tube length prediction (Beckstrand, Ellett, & McDaniel, 2007 [4a]; Gallaher et al., 1993 [3a]; Weibley et 
al., 1987 [4a]).
Note: Short stature is defined as a standing height more than 2 standard deviations (SDs) below the mean (or below 
the 2.5 percentile) for sex (Cohen et al., 2008 [5]).
Note: Mark tube length at the nare for NGT, or corner of the mouth for OGT with indelible permanent marker and 
document amount of tube remaining (external visible length) (EVL) outside the patient in the patient record (Weibley 
et al., 1987 [4a]).
Table: Age-related Height-based (ARHB) Prediction Equations for the Internal Distance to the Body of the Stomach
for Use in Clinical Practice, by Route of Insertion and Age in Children
Note: the distance measured is to the bottom of the distal pore on the tube Beckstrand, (2007) [4a] Used with permission.  
See Figure 1 in the original guideline document for Algorithm: Confirmation of NGT/OGT Placement.
Definitions:
Table of Evidence Levels
a = good quality study; b = lesser quality study
 
Table of Recommendation Strength
Route Age Group (months) Predicted Internal Distance to the Body of the Stomach
Oral 9.1 cm + 0.183 (height cm) + 6 cm + 1.5 cm = 16.6 + 0.183 (height cm)
9.1 cm + 0.183 (height cm) + 8 cm + 3 cm = 20.1 + 0.183 (height cm)
4.5 cm + 0.218 (height cm) + 7.5 cm + 5 cm = 17 + 0.218 (height cm)
Age >121 4. 5cm + 0.218 (height cm) + 9 cm + 5 cm = 18.5 + 0.218 (height cm)
Nasal Age <28 10.1 cm + 0.197 (height cm) + 6 cm + 1.5 cm = 17.6 + 0.197 (height cm)
28 < age < 100 10.1 cm + 0.197 (height cm) + 8 cm + 3 cm = 21.1 + 0.197 (height cm)
100 < age < 121 4.5 cm + (2.7) + 0.218 (height cm) + 6.5 cm + 5 cm = 18.7 + 0.218 (height cm)
Age >121 4.5 cm + (2.7) + 0.218 (height cm) + 9 cm + 5 cm = 21.2 + 0.218 (height cm)
Quality Level Definition
1a  or 1b Systematic review, meta -analysis, or meta-synthesis of multiple studies
2a or 2b Best study design for domain
3a or 3b Fair study design for domain
4a or 4b Weak study design for domain
5 Other: general review, expert opinion, case report, consensus report, or guideline
Strength Definition
"Strongly recommended" There is consensus that benefits clearly outweigh risks and burdens (or vice versa for negative recommendations).
"Recommended" There is consensus that benefits are closely balanced with risks and burdens.
No recommendation made There is a lack of consensus to direct development of a recommendation.
Dimensions: In determining the strength of a recommendation, the development group makes a considered judgment in a consensus process that 
incorporates critically appraised evidence, clinical experience, and other dimensions as listed below.
1.
2.
3.
4.  
5. -effectiveness to healthcare system (balance of cost/savings of resources, staff time, and supplies based on published studies or onsite 
analysis) 
6.
outcome]) 
7.
Clinical Algorithm(s)
A clinical algorithm for the confirmation of nasogastric or orogastric tube (NGT/ORT) placement is provided in the original 
guideline document.
Evidence Supporting the Recommendations
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Type of Evidence Supporting the Recommendations
The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" 
field).
Benefits/Harms of Implementing the Guideline Recommendations
Potential Benefits
-
radiological methods 
-radiological NGT/OGT placement methods contribute to decreased radiation exposure for pediatric patients.  
may contribute to decreased costs. 
Potential Harms
Qualifying Statements
Qualifying Statements
This Best Evidence Statement addresses only key points of care for the target population; it is not intended to be a 
comprehensive practice guideline. These recommendations result from review of literature and practices current at the 
time of their formulation. This Best Evidence Statement does not preclude using care modalities proven efficacious in 
studies published subsequent to the current revision of this document. This document is not intended to impose 
standards of care preventing selective variances from the recommendations to meet the specific and unique requirements 
of individual patients. Adherence to this Statement is voluntary. The clinician in light of the individual circumstances 
presented by the patient must make the ultimate judgment regarding the priority of any specific procedure.
Implementation of the Guideline
Description of Implementation Strategy
An implementation strategy was not provided.
Implementation Tools
Clinical Algorithm
For information about availability, see the Availability of Companion Documents  and Patient Resources  fields below.
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